I hereby certify that this paper is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 582593984 U.S. on the date shown below in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22313-1450.

Dated: May 23, 2007

ignature: (Lori Sims)

Patent Docket No. 577712000200

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Stephen TOMLINSON et al.

Serial No.: 10/534,772

International Filing Date: November 13, 2003

International Appl. No.: PCT/US2003/036459

For: COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT

MODULATORS

Examiner: Not Yet Assigned

Group Art Unit: 1653

# INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

## Patent Docket No. 577712000200

	This In	formation Disclosure Statement is submitted:						
	With the application; accordingly, no fee or separate requirements are required.							
	Befor	e the mailing of a first Office Action after the filing of a Request for Continued						
	Exam	ination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97						
	(e)(1)	has been provided.						
$\boxtimes$	Withi	n three months of the application filing date or before mailing of a first Office Action						
	on the	e merits; accordingly, no fee or separate requirements are required. However, if						
	applio	eable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.						
	After	receipt of a first Office Action on the merits but before mailing of a final Office Action						
	or No	tice of Allowance.						
		A fee is required. A check in the amount of is enclosed.						
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to						
		this submission in duplicate.						
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is						
		believed to be due.						
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the						
	issue	fee.						
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the						
		amount of is enclosed.						
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal						
		form (PTO/SB/17) is attached to this submission in duplicate.						

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

pa-1146250

Application Serial No. 10/534,772

Patent Docket No. 577712000200

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to <a href="Deposit Account No. 03-1952">Deposit Account No. 03-1952</a> referencing 577712000200.

Dated: May 23, 2007

Respectfully submitted,

Jian Xiao

Registration No.: 55,748 MORRISON & FOERSTER LLP 755 Page Mill Road Palo Alto, California 94304-1018 (650) 813-5736

0.4	stitute for form 1449/PTO			Complete if Known		
Sub	issitute for form 1449/PTO			Application Number	10/534,772	
IN	FORMATION	I DI	SCLOSURE	Filing Date	(int'l.) November 13, 2003	
S	TATEMENT E	RY A	APPLICANT	First Named Inventor	Stephen TOMLINSON	
۰				Art Unit	1653	
	(Use as many she	ets as	necess ary)	Examiner Name	Not Yet Assigned	
Sheet	heet 1 of 8		Attorney Docket Number	577712000200		

	U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevan			
Initials*	No.3	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear			
	1.	US-2005/0265995-A1	12-01-2005	Tomlinson et al.	i			
	2.	US-2006/0014681-A1	01-19-2006	Chen et al.				
	3.	US-5,212,071-A	05-18-1993	Fearon et al.				
	4.	US-5,328,470-A	07-12-1994	Nabel et al.				
	5.	US-5,472,939-A	12-05-1995	Fearon et al.				
	6.	US-5,851,528-A	12-22-1998	Ko et al.				
	7.	US-5,949,562-A	09-07-1999	Kubota et al.				
	8.	US-5,949,961-A	09-07-1999	Sharman				
	9.	US-5,981,481-A	11-09-1999	Fearon et al.				
	10.	US-6,140,472-A	10-31-2000	Rosengard et al.				
	11.	US-6,291,239-B1	09-18-2001	Prodinger et al.				
	12.	US-6,432,679-B1	08-13-2002	Mond et al.				
	13.	US-6,458,360-B1	10-01-2002	Fearon et al.				
•	14.	US-6,503,947-B1	01-07-2003	Lipton et al.				
	15.	US-6,521,450-B1	02-18-2003	Atkinson et al.				
	16.	US-6.820.011-B2	11-16-2004	Chen et al.				

		FOREI	GN PATENT	DOCUMENTS		
Examiner	Cite	Foreign Petent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relavant Passages or Relevent Figures Appeer	Γ
Initials*	No.1	Country Code3-Number4-Kind Code5 (# known)	MM-DD-YYYY	Applicant of Cited Document		7
	17.	EP-0 402 226-A1	12-12-1990	Institut National de la Recherche Agronomique		Г
	18.	WO-91/16437-A1	10-31-1991	The Johns Hopkins University		Г
	19.	WO-98/07835-A2, A3	02-26-1998	Sugen, Inc.		r
	20.	WO-04/103288-A2, A3	12-02-2004	New York Society for the Ruptured and Crippled Maintaining the Hospital for Special Surgery et al.		

EXAMINED: Initial I information considered, whether or not claims in a nonformance with MPEP 600. One line important in an incontinuous end not considered, include copy of this time with mest communication to applicant. "Applicants' unique claims need gradual number (optional). "See Knds Codes of CLEFFO Remarks and the claims of the cla

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials						
	21.	Abrahmsen, L. et al. (April 30, 1991). "Engineering Subtilisin and Its Substrates for Efficient Ligation of Peptide Bonds in Aqueous Solution," <i>Biochemistry</i> 30(17):4151-4159.				
*	22.	Ahearn, J.M. et al. (March 1996). "Disruption of the Cr2 Locus Results in a Reduction in B-1a Cells and in an Impaired B Cell Response to T-Dependent Antigen," Immunity 4(3):251-262,				
	23.	Amsterdam, E.A. et al. (January 1995). "Limitation of Reperfusion Injury by a Monoclonal Antibody to C5a During Myocardial Infarction in Pigs," <i>Am. J. Physiol.</i> 268(1):H448-H457.				

Examiner	Date
Signature	Considered
pa- 1146261	

	stitute for form, 1449/PT			Complete if Known		
Suu	Suluie loi lorni (449/P1)			Application Number	10/534,772	
IN	IFORMATIC	N DI	SCLOSURE	Filing Date	(Int'l.) November 13, 2003	
			PPLICANT	First Named Inventor	Stephen TOMLINSON	
٦	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Art Unit	1653	
(Use as many she ets as necess ary)				Examiner Name	Not Yet Assigned	
Sheet	Sheet 2 of 8		Attomey Docket Number	577712000200		

24. Andrews, B.S. et al. (October 1, 1978). "Spontaneous Murine Lupus-like Syndromes. Clinical and Immunogabitological Manifestations in Several Strains," <i>J. Exp. Med.</i> 148(4):1198-1215.  25. Aslam, M. et al. (June 22, 2001). "Folded-Back Solution Structure of Monomeric Factor H of Human Complement by Syndrotrom X-ray and Neutron Scattering, Analytical Ultracentrifugation and Constrained Molecular Modelling," <i>J. Mol. Biol.</i> 309(5):1117-1138.  26. Aubry, J.P. et al. (August 6, 1992). "CD21 is a Ligand for CD23 and Regulates IgE Production." <i>Nature</i> 388(6388):505-507.  27. Bagahawe, K.D. et al. (1988). "Towards Generating Cytotoxic Agents at Cancer Sites," <i>Br. J. Cancer</i> 93:700-703.  28. Bagahawe, K.D. (1989). "Towards Generating Cytotoxic Agents at Cancer Sites," <i>Br. J. Cancer</i> 69:700-703.  29. Bagahawe, K.D. (1989). "Towards Generating Cytotoxic Agents at Cancer Sites," <i>Br. J. Cancer</i> 69:725-281.  20. Barrayl, L. et al. (Julys) 1994). "Cell-Surface Bound Complement Regulatory Activity is Necessary for the <i>in vivo</i> Survival of KDH-8 Rat Hepatoma," <i>Immunology</i> 82(4):522-528.  30. Barriov, P.N. et al. (Julys) 1993). "Solution Structure of a Pair of Complement Modules by Nuclear Magnetic Resonance," <i>J. Mol. Biol.</i> 232:288-294.  31. Battelli, M.G. et al. (1992). "Typhycocyte Killing by x Aanthine-Oxidase-Containing Immunoloxin," <i>Cancer Immunol. Immunoloher</i> , 35.421-425.  32. Bergalson, J.M. et al. (1992). "Typhycocyte Killing by X Panthine-Oxidase-Containing Immunoloxin," <i>Cancer Immunol. Immunoloher</i> , 35.421-425.  33. Brown, V.J. et al. (July/S1993). "1994). "Decay-Accelerating Factor (CD55), A Gyrosylphosphaticylinositol-Anchoned Complement Regulatory Protein, is a Receptor for Several Echonicities." <i>Proc. Natl. Acad. Sci. USA</i> 91(1):396-426-524.  34. Cambier, J-C. (May 1997). "Signalling Processes in Haematopoletic Cells: Positive and Negalies Signatures." <i>Proc. Natl. Acad. Sci. USA</i> 91(1):396-396-399.  34. Cambier, J-C. (May 1997). "Signalling Processes in Hematopoletic Cells: Positive and Regulation			
Human Complement by Synchrotron X-ray and Neutron Scattering, Analytical Ultracentrifugation and Constrained Molecular Molecilling." J. Mol. 806, 309(5):1117-1138.  26. Aubry, J.P. et al. (August 6, 1992). "CD21 is a Ligand for CD23 and Regulates IgE Production." Maler 38(8):38(9):55-507.  27. Bagshawe, K.D. et al. (1988). "A Cytotoxic Agent can be Generated Selectively at Cancer Sistes." Br. J. Cancer 58:700-703.  28. Bagshawe, K.D. et al. (1988). "A Cytotoxic Agent can be Generated Selectively at Cancer Sistes." Br. J. Cancer 58:702-703.  29. Bagshawe, K.D. (1989). "Towards Generating Cytotoxic Agents at Cancer Sites." Br. J. Cancer 50:275-281.  29. Barranyl. L. et al. (August 1994). "Cell-Surface Bound Complement Regulatory Activity is Necessary for the vivo Survival of KDH-R Raft Hepstoma." Immunology, 82(4):525-28.  30. Barlow, P.N. et al. (July S., 1993). "Solution Structure of a Pair of Complement Modules by Nuclear Magnetic Resonance," J. Mol. Biol. 232:258-264.  31. Battelli, M.G. et al. (1992). "I Lymphocyte Killing by a Xanthine-Oxidase-Containing Immunoloxing." Cancer Immunol. Immunoloxies, 324:1-425.  32. Bergelson, J.M. et al. (Liue 21, 1994). "Decay-Accelerating Factor (CD55), A Citycasylphosphalidylinosiol-Anchomed Complement Regulatory Protein, is a Receptor for Several Echoviruses," Proc. Natl. Acad. Sci. USA 91(13):6245-6249.  33. Brown, V.I. et al. (Lily/August 1991). "Molecular and Cellular Machanisms of Receptor-Mediated Endocytosis," DNA and Cell Biology. 10(6):399-409.  34. Cambier, J.C. (May 1997). "Signaling Processes in Heamatopoietic Cells: Positive and Negative Signal Co-operativity in the Immunol System: The BCR, FcyRills, CR2 Paradigm." Biochem. Soc. Trans. 25(2):441-445.  35. Caragina, T.A. et al. (February 15, 2002). "A Tumor-Expressed Inhibitor of the Early but not Leaconplement Lylin Pathway Enhances Tumor Growth in a Rat Model of Human Breast Cancer," Cancer Res. 82(4):1110-1115.  36. Carrol, M.C. (1998). "The Role of Complement and Complement Receptors in Induction and Recep	24.		
Production, "Nature 388(6386):505-507.  27. Bagshawe, K. D. et al. (1988). "A Cytotoxic Agent can be Generated Selectively at Cancer Sites," Br. J. Cancer 58:700-703.  28. Bagshawe, K. D. (1989). "Towards Generating Cytotoxic Agents at Cancer Sites," Br. J. Cancer 68:275-281.  29. Barroy, I. et al. (August 1994). "Cell-Surface Bound Complement Regulatory Activity is Necessary for the in vivo Survival of KDH-8 Rat Hepatoma," Immunology 82(4):522-528.  30. Barroy, P. N. et al. (July 5, 1993). "Solution Structure of a Pair of Complement Modules by Nuclear Magnetic Resonance," J. Mol. Biol. 232:268-284.  31. Battelli, M. C. et al. (1992). "T Lymphocyte Killing by a Xanthine-Oxidase-Containing Immunoloxin," Cener Immunol. Immunoliter, 32-22-285.  32. Bergelson, J.M. et al. (June 21, 1994). "Decay-Accelerating Factor (CD55), A Glycosyphosphadidy/indostoh-Annonad Complement Regulatory Protein, is a Receptor for Several Echoviruses," Proc. Natl. Acad. Sci. USA 91(13):6245-6249.  33. Brown, V.I. et al. (July/August 1991). "Molecular and Cellular Mechanisms of Receptor-Mediated Endocytosis," DMA and Cell Biology 10(6):398-409.  34. Cambier, J-C. (May 1997). "Signaling Processes in Heamatopoietic Cells: Positive and Negative Signal Co-operativity in the Immune System: The BCR, FcyKills, CR2 Paradigm," Biochem. Soc. Trans. 28(2):441-445.  35. Caragina, T.A. et al. (February 15, 2002). "A Tumor-Expressed Inhibitor of the Early but not Late Complement Lytip Pathway Febranaces Tumor Growth in a Rt Model of Human Breast Cancer," Cancer Res. 52(4):1110-1115.  36. Carrel, J.C. et al. (Lily 25, 1990). "Structural Requirements for C3d,g/Epstein-Barr Virus Receptor (CR2/CD21) Ligand Binding, Internalization, and Viral Infection," J. Biol. Chem. 25(5(21):1239-12299.  37. Carroll, M.C. (1998). "The Role of Complement and Complement Receptors in Induction and Regulation of Immunity," Annu. Rev. Immunol. 16:545-568.  38. Carrol, M. C. (1908). "The Role of Complement in B Cell Activation and Tolerance" Advances in Immunology, Down, F.J.	25.	Aslam, M. et al. (June 22, 2001). "Folded-Back Solution Structure of Monomeric Factor H of Human Complement by Synchrotron X-ray and Neutron Scattering, Analytical	
Sites, *Br. J. Cancer 58: 700-703.  28. Bagshawe, K. D. (1989). "Towards Generating Cytotoxic Agents at Cancer Sites," Br. J. Cancer 60:275-281.  29. Baranyl, L. et al. (August 1994). "Cell-Surface Bound Complement Regulatory Activity is Necessary for the in vivo Surival of KDH-8 Rat Hepatoma," Immunology, 82(4):522-528.  30. Bartiov, R.N. et al. (July 5, 1993). "Solution Structure of a Pair of Complement Modules by Nuclear Magnetic Resonance," J. Mol. Biol. 232:288-294.  31. Battelli, M.G. et al. (1992). "T Lymphocyte Killing by a Xanthine-Oxidase-Containing Immunoloxin," Cancer Immunol. Immunolbirs," 35-221-425.  32. Bergelson, J.M. et al. (June 21, 1994). "Decay-Accelerating Factor (CD55), A Glycosylhosphadidyinostol-Anchored Complement Regulatory Protein, Is a Receptor for Several Echoviruses," Proc. Natl. Acad. Sci. USA 91(1):224-56-249.  33. Brown, V.I. et al. (July/August 1991). "Molecular and Cellular Mechanisms of Receptor-Mediciaed Endocytosis," DAM and Cell Biology 10(6):294-609.  34. Cambier, J-C. (May) 1997). "Signaling Processes in Heamatopoletic Cells: Positive and Negative Signal Co-operativity in the Immune System: The BCR, FcyKills, CR2 Paradigm," Signohm. Soc. Trans. 28(2):441-455.  35. Caragina, T.A. et al. (February 15, 2002). "A Tumor-Expressed Inhibitor of the Early but not Late Complement Lytip Pathwey Febrances Tumor Growth in a Rat Model of Human Breast Cancer," Cancer Res. 62(4):1110-1115.  36. Carroll, M.C. (1998). "The Role of Complement and Complement Receptors in Induction and Regulation of Immunity," Annu. Rev. Immunol. 16:545-568.  37. Carroll, M.C. (1998). "The Role of Complement and Complement Receptor in Induction and Regulation of Immunity," Annu. Rev. Immunol. 16:545-568.  38. Carroll, M.C. (2000). "The Role of Complement and Complement Receptors in Induction and Regulation of Immunity," Annu. Rev. Immunol. 16:545-568.  38. Carroll, M.C. (2000). "The Role of Complement and Complement Receptor Simulation of B Lymphocytes," Science 256:1051-107.  40. Cassanovas, J.M. et al. (	26.		
Cancer 60:275-281.  29. Baranyl, L. et al. (Appust 1994). "Cell-Surface Bound Complement Regulatory Activity is Necessary for the <i>in vivo</i> Surivial of KDH-8 Rat Hepatoma," <i>Immunology</i> 82(4):522-528.  30. Bartow, P.N. et al. (July 5, 1993). "Solution Structure of a Pair of Complement Modules by Nuclear Magnetic Resonance," <i>J. Mol. Biol.</i> 232:288-294.  31. Battelli, M. G. et al. (1992). "Tupphocyte Killing by a Xanthine-Oxidase-Containing Immunoloxin," <i>Cancer Immunol Immunoloher</i> . 35.421-425.  32. Bergelson, J.M. et al. (June 21, 1994). "Decay-Accelerating Factor (CD55), A Glycosyphosphatidy in-oxido-Nanored Complement Regulatory Protein, is a Receptor for Serveral Ecthoviruses," <i>Proc. Natl. Acad. Sci. U.S.</i> 9 11(3):522-65249.  33. Brown, V.I. et al. (July/August 1991). "Nolecular and Cellular Mechanisms of Receptor-Mediciale Endocriosis." <i>DNA and Cell Biology</i> 10(6):399-409.  34. Cambier, J.C. (May 1997). "Singailing Processes in Heamatopoletic Cells: Positive and Negative Signal Co-operativity in the Immune System." The BCR, FcyRills, CR2 Paradigm," <i>Slochem. Soc. Trans.</i> 26(2):441-42052). "A Tumor-Expressed Inhibitor of the Early but not Late Complement Lytip Pathway Finances Tumor Growth in a Rat Model of Human Breast Cancer." <i>Cancer Res.</i> 62(4):1110-1115.  36. Caraglin, T.A. et al. (February 15, 2002). "A Tumor-Expressed Inhibitor of the Early but not Late Complement Lytip Pathway Finances Tumor Growth in a Rat Model of Human Breast Cancer." <i>Cancer Res.</i> 62(4):1110-1115.  37. Carroll, M.C. (1998). "The Role of Complement and Complement Receptors in Induction and Regulation of Immunity," <i>Annu. Rev. Immunol.</i> 16:545-558.  38. Carroll, M.C. (1998). "The Role of Complement and Complement Receptor in Induction and Regulation of Immunity," <i>Annu. Rev. Immunol.</i> 16:545-558.  39. Carrol, M.C. (2000). "The Role of Complement on Complement Receptors in Induction and Regulation of Immunity," <i>Annu. Rev. Immunol.</i> 16:545-558.  39. Carrol, M.C. (2000). "The Role of Complement on The Cell Surface and Tolerance" A	27.		
Necessary for the in vivo Survival of KDH-8 Rat Hepatoma, "Immunology 82(4):522-528.  30. Barlow, P.N. et al. (July 5, 1939), "Solution Structure of a Pair of Complement Modules by Nuclear Magnetic Resonance," J. Mol. Biol. 232-268-264.  31. Battelli, M. G. et al. (1992), "Turphocyte Killing by a Xanthine-Oxidase-Containing Immunoloxin," Cancer Immunol. Immunoloter. 35:421-425.  32. Bergelson, J.M. et al. (July 21, 1994), "Desay-Accelerating Factor (CDS5), A. Glycosyphosphaticylinositol-Anchoned Complement Regulatory Protein, Is a Receptor for Several Echonicinses," Proc. Natl. Acad. Sci. USA 91(19):624-569.  33. Brown, V.I. et al. (July/August 1991), "Molecular and Cellular Mechanisms of Receptor-Mediated Endocytosis," DNA and Cell Biology, 10(6):394-409.  44. Cambier, J.C. (May 1997), "Signalling Processes in Haematopoletic Cells: Positive and Negative Signal Co-operativity in the Immune System: The BCR, FcyRills, CR2 Paradigm," Sciochem. Soc. Trans. 28(2):441-42002), "A Turmor-Expressed Inhibitor of the Early but not Late Complement Lytio Pathway Enhances Turnor Growth in a Rat Model of Human Breast Cancer," Cancer Res. 52(4):1110-1115.  36. Carroll, R.C. (1998), "The Role of Complement and Complement Receptor in Induction and Recyptor (CR2/CD21) Ligand Binding, Internalization, and Viral Infaction," J. Biol. Chem. 26(5):11:2293-12299.  37. Carroll, M.C. (1998), "The Role of Complement and Complement Receptors in Induction and Regulation of Immunity," Annu. Rev. Immunol. 16:545-568.  38. Carroll, M.C. (2000), "The Role of Complement in B Cell Activation and Tolerance" Advances in Immunology, Down, F.J. ed., Academic Press, Inc., 7461-88.  39. Carrol, M.C. (2000), "The Role of Complement in B Cell Activation and Tolerance" Advances in Immunology, Down, F.J. ed., Academic Press, Inc., 7461-88.  39. Carrol, M.C. (2000), "The Role of Complement of Two CD46 Domains Reveals an Extended Measter Virus-Binding Surface," EMDOJ. 1, 19(11):2911-2922.  41. Chen, SH. et al. (April 12, 1994) "Cene Therapy for Brain Turno	28.		
Nuclear Magnetic Resonance," J. Mol. Biol. 232:268-284.  31. Battelli, M. G. et al. (1992). "Lymphocyte Killing by a Xanthine-Oxidase-Containing Immunoloxin," Cancer Immunol. Immunolber. 35:421-425.  32. Bergelson, J. M. et al. (Juley 21, 1994). "Decay-Accelerating Factor (CD55). A Glycosyphosphatidylinositol-Anchoned Complement Regulatory Protein, is a Receptor for Several Echonivoruses," Proc. Natl. Acad. Sci. USA 91(13):624-569.  33. Brown, V.I. et al. (July/August 1991). "Molecular and Cellular Mechanisms of Receptor-Mediated Endocytosis," DNA and Cell Biology 10(6):399-409.  34. Cambier, JC. (May 1997). "Signalling Processes in Haematopoletic Cells: Positive and Negative Signal Co-operativity in the Immune System: The BCR, FcyRills, CR2 Paradigm," Biochem. Soc. Trans. 28(2):441-45.  35. Caraging, T.A. et al. (February 15, 2002). "A Tumor-Expressed Inhibitor of the Early but not Late Complement Lytic Pathway Enhances Tumor Growth in a Rat Model of Human Breast Cancer, Cancer Res. 52(4):1110-1113.  36. Carrol, R.C. (1941). "Simple System of Complements of C3d, glepstein-Barr Virus Receptor (CR2/CD21) Ligand Binding, Internalization, and Viral Infection," J. Biol. Chem. 26(5):11229-112299.  37. Carroll, M.C. (1998). "The Role of Complement and Complement Receptors in Induction and Regulation of Immunity," Annu. Rev. Immunol. 16:545-568.  36. Carroll, M.C. (2000). "The Role of Complement in B Cell Activation and Tolerance" Advances in Immunology, Down, F.J. ed., Academic Press, inc., 7461-88.  37. Carroll, M.C. (2000). "The Role of Complement in B Cell Activation and Tolerance" Advances in Immunology, Down, F.J. ed., Academic Press, inc., 7461-88.  38. Carroll, M.C. (2000). "The Role of Complement for C004 Domains Reveals an Extended Measles Virus-Binding Surface," EMDO. J. 19(11):2911-2922.  41. Chen, S. H. et al. (April 12, 1994). "Cene Therapy for Brain Tumors. Regression of Experimental Giomas by Adenovirus-Mediated Gene Transfer in vivo," Proc. Natl. Acad. Sci. USA 19(8):3054-3057.  42. Chen, S. H. et a	29.		
Immunotoxin," Cancer Immunol. Immunothers. 35: 421-425.  32. Bergelson, J.M. et al. (June 21. 1994). "Decay-Accelerating Factor (CD55), A Glycosyphosphatidylinositol-Anchored Complement Regulatory Protein, is a Receptor for Several Echonicuses," Proc. Natl. Acad. Sci. USA 91(13):624-5649.  33. Brown, V.I. et al. (July/August 1991). "Molecular and Cellular Mechanisms of Receptor-Mediated Endocytosis," DNA and Cell Biology 10(6):399-409.  34. Cambier, J-C. (May 1997). "Signalling Processes in Haematopoietic Cells: Resitive and Negative Signal Cooperatively in the Immune System: The BCR, FcyRillb, CR2 Paradigm," Biochem. Soc. Trans. 25(2):441-445.  35. Caragine, T.A. et al. (February 15, 2002). "A Tumor-Expressed Inhibitor of the Early but not Lac Complement Lybic Pathway 15, 2002). "A Tumor Growth in a Rat Model of Human Breast Canoer," Gencer Res. 52(4):110-1115.  36. Caragine, T.A. et al. (February 15, 2002). "No Tumor Growth in a Rat Model of Human Breast Canoer," Gencer Res. 52(4):110-1115.  37. Caroll, J.C. et al. (July 25, 1990). "Structural Requirements for C3d, g/Epstein-Barr Virus Receptor (R2CD21) Ligand Binding, Internalization, and Viral Infection," J. Biol. Chem. 23(5):(1):1239-12299.  37. Caroll, M.C. (1998). "The Role of Complement and Complement Receptors in Induction and Regulation of Immunity," Annu. Rev. Immunol. 16:545-568.  38. Caroll, M.C. (2000). "The Role of Complement in B Cell Activation and Tolerance" Advances in Immunology, Down, F.J. ed., Academic Press, Inc., 7461-88.  39. Carter, R.H. et al. (April 3, 1992). "CD191 Lowening the Threshold for Antigen Receptor Situation of Dynamics Reveals an Extended Measles Virus-Binding Surface," EMDO, 19(11):2911-2922.  41. Chen, S.H. et al. (April 2, 1994). "Gene Therapy for Brain Tumors. Regression of Experimental Gillomas by Adenovirus-Mediated Gene Transfer in vivo," Proc. Natl. Acad. Sci. USA 19(8):3054-3057.  42. Chen, S.H. et al. (April 2, 1994). "Gene Therapy for Brain Tumors. Regression of Experimental Gillomas by Adenovirus-Mediated Gene	30.		
Glycosyphosphalidylinosiol-Anchored Complement Regulatory Protein, is a Receptor for Several Echonicuses, *Proc. Nat. Acad. Sci. USA 91(13):6245-6249.  33. Brown, VI. et al. (July/August 1991). *Molecular and Cellular Mechanisms of Receptor-Mediated Endocytosiss.** (DNA and Cell Biology). 10(6):399-409.  34. Cambier, J-C. (May 1997). *Signalling Processes in Haematopoietic Cells: Resitive and Negative Signal Cooperativity in the Immune System: The BCR, FcyRills, CR2 Paradigm, "Biochem. Soc. Trans. 25(2):441-445.  35. Carcigline, T.A. et al. (February 15, 2002). *A Tumor-Expressed Inhibitor of the Early but not Liconomic Cancer fos. 52(2):441-445.  36. Carcil, T.A. et al. (February 15, 2002). *A Tumor-Expressed Inhibitor of the Early but not Liconomic Cancer fos. 52(4):1110-1115.  36. Carcil, J.C. et al. (July 25, 1990). Structural Requirements for C3d, g/Epstein-Barr Virus Receptor (R2/CD21) Ligand Binding, Internalization, and Viral Infection, "J. Biol. Chem. 25(5)(2), 12239-12239.  37. Carroll, M.C. (1998). *The Role of Complement and Complement Receptors in Induction and Regulation of Immunity," Annu. Rev. Immunol. 16:545-568.  38. Carroll, M.C. (2000). *The Role of Complement in B Cell Activation and Toleranco" Advances in Immunology, Dison, F.J. ed., Academic Press, Inc., 746:1-88.  39. Carter, R.H. et al. (April 3, 1992). *CD181 Lowering the Threshold for Antigen Receptor Simulation of B Lymphocytes," Science 256:105-107.  40. Cassanovas, J.M. et al. (1999). "Crystal Structure of Two CD46 Domains Reveals an Extended Measles Virus-Binding Surface," EMDO-1. 18(11):2911-2922.  41. Chen, S. et al. (Lune 1, 2000). "CD59 Expressed on a Tumor Cell Surface Modulates Decay-Accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neurobastom," Cancer Res Cell (11), 301-3018.  42. Chen, S. et al. (Lune 1, 2000). "CD59 Expressed on a Tumor Cell Surface Modulates Decay-Accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neurobastom and Cell Controls and Controls and	31.		
Mediated Endocytosis," DNA and Cell Biology 10(6):399-409.  34. Cambier, J-C, (May 1997). "Signaling Processes in Heamatopoietic Cells: Positive and Negative Signal Co-operativity in the Immune System: The BCR, FcyRille, CR2 Paradigm." Biochem. Soc. Trans. 25(2):441-445.  35. Caragine, T.A. et al. (February 15, 2002). "A Tumor-Expressed Inhibitor of the Early but not Lack Complement Lytio Pathway Enhances Tumor Growth in a Rat Model of Human Breast Cancer," Cancer Res. 52(4):1110-1115.  36. Carrol, J.C. et al. (Lyll 25, 1990). "Structural Requirements for C3d, g/Epstein-Barr Virus Receptor (CR2/CD21) Ligand Binding, Internatization, and Viral Infection," J. Biol. Chem. 28(5(1):1299-12299.  37. Carroll, M.C. (1998). "The Role of Complement and Complement Receptors in Induction and Regulation of Immunity," Annu. Rev. Immunol. (16:545-568.  38. Carroll, M.C. (2000). "The Role of Complement in B Cell Activation and Tolerance" Advances in Immunology, Dixon, F.J. ed., Academic Press, Inc., 7461-188.  39. Carter, R.H. et al. (April 3, 1992). "CD19 Lowering the Threshold for Antigen Receptor Stimulation of B Lymphocytes," Science 256:105-107.  40. Cassanovas, J.M. et al. (1999). "Crystal Structure of Two CD46 Domains Reveals an Extended Measlew Yirus-Binding Surface," EMBOD, 11(1):1211-2922.  41. Chen, S.H. et al. (April 12, 1994). "Gene Therapy for Brain Tumors. Regression of Experimental Gilomas by Adenovirus-Mediated Gene Transfer in vivo," Proc. Natl. Acad. Sci. U.SA. 19(8):3054-3057.  42. Chen, S. et al. (Lune 1, 2000). "CD59 Expressed on a Tumor Cell Surface Modulates Decay-Accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neurobastoma", Cancer Res. 60(11), 3013-3018.  43. Christiansen, D. et al. (March 1996). "A Functional Analysis of Recombinant Soluble CD46 in vivo and a Comparison with Recombinant Soluble Forms of CD55 and CD35 in vitro."  European Journal of Immunology, 26(3):578-585.	32.	Glycosylphosphatidylinositol-Anchored Complement Regulatory Protein, is a Receptor for	
Negative Signal Co-operativity in the Immune System: The BCR, FcyRIIB, CR2 Paradigm."  Biochem. Soc. Trans. 25(2):444-45.  35. Caragine, T.A. et al. (February 15, 2002). "A Tumor-Expressed Inhibitor of the Early but not Late Complement Lytio Pathway Fehanaces Tumor Growth in a Rat Model of Human Breast Cancer," Cancer Res. 62(4):1110-1115.  36. Carrol, J.C. et al. (Lyll 25, 1990). "Structural Requirements for C3d,g/Epstein-Barn Virus Receptor (CR2/CD21) Ligand Binding, Internalization, and Viral Infection," J. Biol. Chem. 28(5(21):1299-1299).  37. Carroll, M.C. (1998). "The Role of Complement and Complement Receptors in Induction and Regulation of Immunity," Annu. Rev. Immunol. (18-545-568.  38. Carroll, M.C. (2000). "The Role of Complement in B Cell Activation and Tolerance" Advances in Immunology, Dixon, F.J. ed., Academic Press, Inc., 7461-88.  39. Carter, R.H. et al. (April 3, 1992). "CD19 Lowering the Threshold for Antigen Receptor Simulation of B Lymphocytes," Science 256: 105-107.  40. Cassanovas, J.M. et al. (1999). "Crystal Structure of Two CD46 Domains Reveals an Extended Measles Virus-Binding Surface," EMBOJ. 18(11):2911-2922.  41. Chen, S.H. et al. (April 12, 1994). "Gene Therapy for Brain Tumors: Regression of Experimental Giomas by Adenovirus-Mediated Gene Transfer in vivo," Proc. Natl. Acad. Sci. U.SA. 19(8):3054-3057.  42. Chen, S. et al. (Lune 1, 2000). "CD59 Expressed on a Tumor Cell Surface Modulates Decay-Accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neurobastoma", Cancer Res. 60(11):3013-3018.  43. Christiansen, D. et al. (March 1996). "A Functional Analysis of Recombinant Soluble CD46 in vivo and a Companison with Recombinant Soluble Forms of CD55 and CD35 in vitro."  European Journal of Immunology. 26(3):578-595.  44. Clemenza, L. et al. (Ocobber 1, 2000). "Structure-Guided Identification of C3d Residues	33.	Mediated Endocytosis," DNA and Cell Biology 10(6):399-409.	
Late Complement Lytic Pathway Enhances Tumor Growth in a Rat Model of Human Breast Cancer," Cancer Res. 82(4):110-1115.  36. Carel, J.C. et al. (July 25, 1990). "Structural Requirements for C3d, g/Epstein-Barr Virus Receptor (CR2/CD21) Ligand Binding, Internalization, and Viral Infection," J. Biol. Chem. 265(21):12293-12299.  37. Carrol, M.C. (1998). "The Role of Complement and Complement Receptors in Induction and Regulation of Immunity," Annu. Rev. Immunol. 16:545-568.  38. Carrol, M.C. (2000). "The Role of Complement in B Cell Activation and Tolerance" Advances in Immunology, Dixon, F.J. ed., Academic Press, Inc., 74:61-98.  39. Carter, R.H. et al. (April 3, 1992). "CD19. Lowering the Threshold for Antigen Receptor Silmulation of El Lymphocytes," Science 256:105-107.  40. Cassanovas, J.M. et al. (1999). "Crystal Structure of Two C046 Domains Reveals an Extended Measles Virus-Binding Surface," EMBO J. 18(11):2911-2922.  41. Chen, S.H. et al. (April 12, 1994). "Gene Therapy for Brain Tumors: Regression of Experimental Ciliomas by Adenovirus-Mediated Gene Transfer in vivo," Proc. Natl. Acad. Sci. U.SA. 19(18):3054-3057.  42. Chen, S. et al. (Lune 1, 2000). "CD59 Expressed on a Tumor Cell Surface Modulates Decay-Accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neuroblastoma," Cancer Res. 60(11):3013-3018.  43. Christiansen, D. et al. (March 1996). "A Functional Analysis of Recombinant Soluble CD46 in vivo and a Compansion with Recombinant Soluble Forms of CD55 and CD35 in viro." European Journal of Immunology. 28(3):578-585.	34.	Negative Signal Co-operativity in the Immune System: The BCR, FcyRIIB, CR2 Paradigm,"	
Receptor (CR2/CD21) Ligand Binding, Internatization, and Viral Infection," J. Biol. Chem. 285(21):1299-1299.  37. Carroll, M.C. (1998). "The Role of Complement and Complement Receptors in Induction and Regulation of Immunity," Annu. Rev. Immunol. (18-54-568).  38. Carroll, M.C. (2000). "The Role of Complement in B Cell Activation and Tolerance" Advances in Immunology, Dixon, F.J. ed., Academic, Press, Inc., 74:61-18.  39. Carter, R.H. et al. (April 3, 1992). "CD19 Lowering the Threshold for Antigen Receptor Simulation of B Lymphocytes," Science 256:105-107.  40. Cassanovas, J.M. et al. (1999). "Crystal Structure of Two CD46 Domains Reveals an Extended Measlew Virus-Binding Surface," EMBOJ. 18(11):2911-2922.  41. Chen, S.H. et al. (April 12, 1994). "Gene Therapy for Brain Tumors: Regression of Experimental Gilomas by Adenovirus-Mediated Gene Transfer in vivo," Proc. Natl. Acad. Sci. U.SA. 19(8):3054-3057.  42. Chen, S. et al. (Lune 1, 2000). "CD59 Expressed on a Tumor Cell Surface Modulates Decay-Accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neurobastoma." Cancer Res. 60(11):3013-3018.  43. Christiansen, D. et al. (March 1996). "A Functional Analysis of Recombinant Soluble CD46 in vivo and a Comparison with Recombinant Soluble Forms of CD55 and CD35 in vitro."  European Journal of Immunology. 26(3):578-595.  44. Clemenza, L. et al. (Ocobber 1, 2000). "Structure-Guided Identification of C3d Residues	35.	Late Complement Lytic Pathway Enhances Tumor Growth in a Rat Model of Human Breast	
Regulation of Immunity," Annu. Rev. Immunol. 16:345-568.  38. Cardil, M.C. (2000). "The Role of Complement in B Cell Activation and Tolerance" Advances in Immunology, Dixon, F.J. ed., Academic Press, Inc., 74:61-88.  39. Carter, F.H. et al. (April 3, 1992). "CD19. Lowering the Threshold for Antigen Receptor Slimulation of 8 Lymphocytes," Science 256:105-107.  40. Cassanovas, J.M. et al. (1999). "Crystal Structure of Two CD46 Domains Reveals an Extended Measies Virus-Binding Surface," EMBO J. 18(11):2911-2922.  41. Chen, S-H. et al. (April 12, 1994). "Gene Therapy for Brain Tumors: Regression of Experimental Climonas by Adenovirus-Mediated Gene Transfer in vivo," Proc. Natl. Acad. Sci. U.SA. 19(8):3054-3057.  42. Chen, S. et al. (June 1, 2000). "CD59 Expressed on a Tumor Cell Surface Modulates Decay-Accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neuroblastoma," Cancer Res Golf1):3013-3018.  43. Christiansen, D. et al. (March 1996). "A Functional Analysis of Recombinant Soluble CD46 in vivo and a Companison with Recombinant Soluble Forms of CD55 and CD35 in viro." European Journal of Immunology. 28(3):578-585.  44. Clemenza, L. et al. (Ocobber 1, 2000). "Structure-Guided Identification of C3d Residues	36.	Receptor (CR2/CD21) Ligand Binding, Internalization, and Viral Infection," J. Biol. Chem.	
in Immunology, Dixon, F.J. ed., Academic Press, Inc., 74.61-88.  39. Carter, R.H. et al. (April 3, 1992); "CD19 Lovering the Threshold for Anligen Receptor Slimulation of B Lymphocytes," Science 256: 105-107.  40. Casanovas, JM. et al. (1999). "Orpstal Structure of Two CD46 Domains Reveals an Extended Measles Virus-Binding Surface," EMBO J. 18(11):2911-2922.  41. Chen, S-H. et al. (April 12, 1994). "Gene Therapy for Brain Tumors: Regression of Experimental Cliomas by Adenovirus-Mediated Gene Transfer in vivo," "Proc. Natl. Acad. Sci. USA 1918):3054-3057.  42. Chen, S. et al. (June 1, 2000). "CD59 Expressed on a Tumor Cell Surface Modulates Decay-Accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neuroblastoma," Cancer Res City 11):301-3018.  43. Christiansen, D. et al. (March 1996). "A Functional Analysis of Recombinant Soluble CD46 in vivo and a Compansion with Recombinant Soluble Forms of CD55 and CD35 in vitro." European Journal of Immunology 28(3):578-585.  44. Clemenza, L. et al. (October 1, 2000). "Structure-Guided Identification of C3d Residues	37.	Carroll, M.C. (1998). "The Role of Complement and Complement Receptors in Induction and Regulation of Immunity," <i>Annu. Rev. Immunol.</i> 16:545-568.	
Stimulation of B Lymphocytes," Science 256: 105-107.  40. Cassanovas, JM et al. (1999) "Cystal Structure of Two CD46 Domains Reveals an Extended Measles Virus-Binding Surface," EMBO J. 18(11):2911-2922.  41. Chen, S-H. et al. (April 12, 1994). "Gene Therapy for Brain Tumors Regression of Experimental Gliomas by Adenovirus-Mediated Gene Transfer in vivo," Proc. Natl. Acad. Sci. USA 19(8):3094-3097.  42. Chen, S. et al. (June 1, 2000). "CD59 Expressed on a Tumor Cell Surface Modulates Decay-Accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neuroblastoma," Cancer Res Solf (11):3013-3018.  43. Christiansen, D. et al. (March 1996). "A Functional Analysis of Recombinant Soluble CD46 in vivo and a Companison with Recombinant Soluble Forms of CD55 and CD35 in vitro," European Journal of Immunology. 28(3):578-585.  44. Clemenza, L. et al. (October 1, 2000). "Structure-Guided Identification of C3d Residues	38.		
Extended Measles Virus-Binding Surface, *EMBO J. 18(11):2911-2922.  41. Chen, S-H et al. (April 12, 1994). "Gene Therapy for Brain Tumors: Regression of Experimental Gliomas by Adenovirus-Mediated Gene Transfer in vivo," *Proc. Natl. Acad. Sci. U.SA 91(8):3054-3057.  42. Chen, S. et al. (June 1, 2000). "CD59 Expressed on a Tumor Cell Surface Modulates Decay-Accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neuroblastoma; "Cancer Ress Oil", 3013-3014.  43. Christiansen, D. et al. (March 1996). "A Functional Analysis of Recombinant Soluble CD46 in vivo and a Companison with Recombinant Soluble Forms of CD55 and CD35 in vitro," *European Journal of Immunology 26(3):578-585.  44. Clemenza, L. et al. (October 1, 2000). "Structure-Guided Identification of C3d Residues	39.		
Experimental Gliomas by Adenovirus-Mediated Gene Transfer in vivo," Proc. Natl. Acad. Sci. USA 11(8):0346-3057.  42. Chen, S. et al. (June 1, 2000). "CD59 Expressed on a Tumor Cell Surface Modulates Decay-Accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neuroblastoma," Cancer Res. 50(11):3013-3018.  43. Christiansen, D. et al. (March 1996). "A Functional Analysis of Recombinant Soluble CD46 in vivo and a Companison with Recombinant Soluble Forms of CD55 and CD35 in vitro," European Journal of Immunology. 26(3):578-585.  44. Clemenza, L. et al. (October 1, 2000). "Structure-Guided Identification of C3d Residues	40.		
Accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neuroblastoma." Cancer Res. Solf1),3013-3018.  43. Christiansen, D. et al. (March 1996). "A Functional Analysis of Recombinant Soluble CD46 in vivo and a Comparison with Recombinant Soluble Forms of CD55 and CD35 in vitro."  European Journal of Immunology 26(3):578-585.  44. Clemenza, L. et al. (October 1, 2000). "Structure-Guided Identification of C3d Residues	41.	Experimental Gliomas by Adenovirus-Mediated Gene Transfer in vivo," Proc. Natl. Acad. Sci.	
wivo and a Comparison with Recombinant Soluble Forms of CD55 and CD35 in vitro,"  European Journal of Immunology 26(3):578-585.  44. Clemenza, L. et al. (October 1, 2000). "Structure-Guided Identification of C3d Residues	42.	Accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neuroblastoma," Cancer Res. 60(11):3013-3018.	
44. Clemenza, L. et al. (October 1, 2000). "Structure-Guided Identification of C3d Residues	43.	vivo and a Comparison with Recombinant Soluble Forms of CD55 and CD35 in vitro,"	
	44.	Clemenza, L. et al. (October 1, 2000). "Structure-Guided Identification of C3d Residues Essential for Its Binding to Complement Receptor 2 (CD21)," J. Immunol. 165(7):3839-3848.	

Examiner I	Date	
Signature	0	
Signature	Considered	

	estitute for form 1449/PTO			Complete if Known		
Suc	stitute for form 1449/P10			Application Number	10/534,772	
IN	FORMATION	I DI	SCLOSURE	Filing Date	(Int'l.) November 13, 2003	
s	TATEMENT E	RY A	APPLICANT	First Named Inventor	Stephen TOMLINSON	
ľ	.,			Art Unit	1653	
	(Use as many she	ets as	necess ary)	Examiner Name	Not Yet Assigned	
Sheet	Sheet 3 of 8		Attomey Docket Number	577712000200		

45.	Davies, A. et al. (September 1, 1989). "CD59, an Ly-6-Like Protein Expressed in Human Lymphoid Cells, Regulates the Action of the Complement Membrane Attack Complex on Homologous Cells," Journal of Experimental Medicine	
46.	de Córdoba, S.R. et al. (2004). "The Human Complement Factor H: Functional Roles, Genetic Variations and Disease Associations," <i>Molecular Immunology</i> 41:355-367.	
47,	Dempsey, P.W. et al. (January 19, 1996). "C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity," Science 271:348-350.	
48.	Dev, S.B. et al. (January 1994). "Electrochemotherapy - A Novel Method of Cancer Treatment," Cancer Treat. Rev. 20(1):105-115.	
49.	Diefenbach, R.J. et al. (March 1, 1995). "Mutation of Residues in the C3dg Region of Human Complement Component C3 Corresponding to a Proposed Binding Site for Complement Receptor Type 2 (CR2, CD21) Does Not Abolish Binding of iC3b or C3dg to CR2." J. Immunol. 154(9):2303-2320.	
50.	Dierich, M.P. et al. (November 1988). "Structural and Functional Relationships Among Receptors and Regulators of the Complement System," <i>Mol. Immunol.</i> 25(11):1043-1051.	
51.	Dörig, R.E. et al. (October 22, 1993). "The Human CD46 Molecule Is a Receptor for Measles Virus (Edmonston Strain)," Cell 75(2):295-305.	
52.	Duits, A.J. et al. (1991), "Selective Enhancement of Leu-Cam Expression by Interleukin 6 During Differentiation of Human Promonocytic U937 Cells," Scand. J. Immunol. 33(2):151- 159.	
53.	Edwards, A.O. et al. (April 15, 2005). "Complement Factor H Polymorphism and Age-Related Macular Degeneration," Science 308(5720):421-424.	
54.	Fearon, D.T. (October 1998). "The Complement System and Adaptive Immunity," Semin. Immunol. 10(5):355-361.	
55.	Fearon, D.T. et al. (1995). "The CD19/CR2/TAPA-1 Complex of B Lymphocytes: Linking Natural to Acquired Immunity," Annu. Rev. Immunol. 13:127-149.	П
56.	Fingeroth, J.D. et al. (July 1984). "Epstein-Barr Virus Receptor of Human B Lymphocytes is the C3d Receptor CR2," Proc. Natl. Acad. Sci. USA 81(14):4510-4514.	
57.	Fingeroth, J.D. et al. (January 1989). "Identification of Murine Complement Receptor Type 2," Proc. Natl. Acad. Sci. USA 86(1):242-246.	
58.	Frémeaux-Bacchi, V. et al. (December 1998). "Soluble CD21 Induces Activation and Differentiation of Human Monocytes Through Binding to Membrane CD23," Eur. J. Immunol. 28:4268-4274.	
59.	Girardi, G. et al. (December 2003). "Complement C5a Receptors and Neutrophils Mediate Fetal Injury in the Antiphospholipid Syndrome," <i>J. Clin. Invest.</i> 112(11):1644-1654.	
60.	Goodford, P.J. (July 1985). "A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules," J. Med. Chem. 28(7):849- 857.	
61.	Gordon, J. (September 1994). "B-cell Signaling via the C-type Lectins CD23 and CD72," Immunol. Today 15(9):411-417.	
62.	Guthridge, J.M. et al. (November 15, 2001). "Epitope Mapping Using the X-Ray Crystallographic Structure of Complement Receptor Type 2 (CR2)/CD21: Identification of a Highly Inhibitory Monoclonal Antibody That Directly Recognizes the CR2-C3d Interface," J. Immunol. 167:5758-5766.	
63.	Guthridge, J.M. et al. (May 22, 2001). "Structural Studies in Solution of the Recombinant N- Terminal Pair of Short Consensus/Complement Repeat Demains of Complement Receptor Type 2 (CR2/CD21) and Interactions with its Ligand C3dg." Biochemistry 40:5931-5941.	
64.	Hageman, G.S. et al. (May 17, 2005). "A Common Haplotype in the Complement Regulatory Gene Factor H ( <i>HF1/CFH</i> ) Predisposes Individuals to Age-Related Macular Degeneration," <i>Proc. Natl. Acad. Sci. USA</i> 102(20):7227-7232.	

Examiner	Date
Signature	Considered

C. 4	Substitute for form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known			
Sub	stitute for form 1449/P1	U		Application Number	10/534,772	
IN	FORMATIC	ON DI	SCLOSURE	Filing Date	(Int'l.) November 13, 2003	
				First Named Inventor	Stephen TOMLINSON	
_	., .,,,			Art Unit	1653	
	(Use as many	sheets as	necess ary)	Examiner Name	Not Yet Assigned	
Sheet	4	of	8	Attorney Docket Number	577712000200	

65. Haines, J.L. et al. (April 15, 2005). "Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration," Science, 308, 491-421.  66. Harris, C.L. et al. (November 2002). "Tailoring Anti-Complement Therapeutics," Biochemical Society, Transactions 30(6):1019-1026.  67. Hebell, T. et al. (October 4, 1991). "Suppression of the Immune Response by a Soluble Complement Receptor 8 Lymphocytes," Science 254:102-105.  68. Heyman, B. (2000). "Regulation of Antibody Responses via Antibodies, Complement, and Fc Receptors," Ann. Rov. Immunol. 18:709-737.  69. Higgins, P.J. et al. (March 15, 1997). "Soluble Chimeric Complement Inhibitory Protein That Possesses Both Decay-Accelerating and Factor I Cofactor Activities," J. Immunol. 158(6):2872-2881.  70. Helers, V.M. (1989). "Complement Receptors" in The Year Inmunology 1988, Sellular, Molecular and Clinical Aspects, Cruse, J.M. et al. eds., Basel, Karger, 4:231-240.  71. Homeister, J.W. et al. (February 1, 1993). "Soluble Complement Receptor Type 1 Prevents Human Complement-Mediated Damage of the Rabbit Isolated Heart," J. Immunol. 150(3):1055-1064.  72. Hori, Y. et al. (December 1999). "Crry, a Complement Regulatory Protein, Modulates Renal Immunolosis in March 1997. "Regulatory Int. 56(6):2906-2108.  73. Haus, S.H. et al. (2003). "Chronic Progression of Tubulointerstitial Damage in Proteinuria (Rubry) Int. 56(6):2906-2108.  74. Hughes, B.J. et al. (November 15, 1999). "Monotonal Antibody Targeting of Liposomes to Mouse Lung in Vivo." Cancer Research 49(22):5214-6220.  75. Humblet, C. et al. (1993). "30 Database Searching and Docking Strategies" Chapter 29 In Topics in Drug Design and Discovery" Section VI In Animal Reports in Medicinal Chemistry, Bristol, J.A. et al. eds., Academic Press, Inc.: San Diego, CA, 28275-283.  76. International Search Report mailed September 15, 2004, for PCT Application No. PCT/US0/336496 filed November 13, 2003, three pages.  77. Józsi, M. et al. (1991). "1019. "Database Searching and Docking Strategies" Chapter 29 In Topi			
Society Transactions 30(6):1019-1026.  67. Hebell, T et al. (October 4, 1991) "Suppression of the Immune Response by a Soluble Complement Receptor of B Lymphocytes," Science 264-102-105.  68. Hebell, T et al. (October 4, 1991) "Suppression of the Immune Response by a Soluble Complement Receptor of B Lymphocytes," Science 264-102-105.  69. Heyman, B (2000) "Regulation of Antibody Responses via Antibodies, Complement, and F c Receptors," Ann. Rev. Immunol. 18:709-737.  69. Higgins, P.J. et al. (March 15, 1997). "Soluble Chimeric Complement Inhibitory Protein That Possesses Both Decay-Accelerating and Factor I Cofactor Activities," J. Immunol. 158(6):2872-2881.  70. Holers, V.M. (1989). "Complement Receptors" in The Year In Immunology 1988, Cellular, Molecular and Citical Aspects, Cruse. J.M. et al. eds., Basel, Kanger. 4:231-240.  71. Horeister, J.W. et al. (February 1, 1993). "Soluble Complement Receptor Type 1 Prevents Human Complement-Mediated Damage of the Rabbit tsolated Heart," J. Immunol. 150(3):1055-1064.  72. Hori, Y. et al. (December 1999). "Crry, a Complement Requistory Protein, Modulates Renal Interstitial Disease Induced by Proteinuria," Kidney Int., 55(6):2096-2106.  73. Hau, S.H.H. et al. (2003). "Chronic Progression of Tubulointerstial Damage in Proteinuria Renal Disease Is Mediated by Complement Activation: A Therapeutic Role for Complement Inhibitors" J. Am. Soc. Nephrol. 14:S186-S191.  74. Hughes, B.J. et al. (November 15, 1989). "Monoclonal Antibody Targeting of Liposomes to Mouse Lung in Vivo." Cancer Research 49(2):E214-6220.  75. Humblet, C. et al. (1993). "Do Babase Searching and Docking Strategies" Chapter 29 In Trojos in Drug Design and Discovery" Section Vin Animal Reports in Medical Chemistry, Bristol, J.A. et al. eds., Academic Press, Inc.: San Diego, CA, 28:275-283.  76. International Search Report mailed September 15, 2004, for PCT Application No. PCT/US00/36499 filed November 19, 2003, three pages.  77. Jozz, M. et al. (2004). "Attachment of the Soluble Complement Reputator Factor	65.	Haines, J.L. et al. (April 15, 2005). "Complement Factor H Variant Increases the Risk of Age- Related Macular Degeneration," Science 308:419-421.	
Complement Receptor of B Lymphocytes," Science 254:102-105.  68. Heyman, B (2000). Regulation of Antibody Responses via Antibodies, Complement, and Fo Receptors," Ann. Rev. Immunol. 18:709-737.  69. Higgins, P.J. et al. (March 15, 1997). "A Souble Chimeric Complement Inhibitory Protein That Possesses Both Decay-Accelerating and Factor I Cofactor Activities," J. Immunol. 158(6):2872-2881.  70. Holers, V.M. (1989). "Complement Receptors" in The Year In Immunology 1988, Cellular, Molecular and Cilinical Aspects, Cruse, J.M. et al. eds., Basel, Kanger, 4:231-240.  71. Horeister, J.W. et al. (February 1, 1993). "Soluble Complement Receptor Type 1 Prevents Human Complement-Mediated Damage of the Rabbit Isolated Heart," J. Immunol. 150(3):1055-1064.  72. Hofr, Y. et al. (December 1999). "Crry, a Complement Requisitory Protein, Modulates Renal Interetitial Disease Induced by Proteinuria." Kidney Int., 55(6):2098-2106.  73. Hay, S.H. et al. (2003). "Choroir Progression of Tubulointerstaila Damage in Proteinuric Renal Disease Is Mediated by Complement Activation: A Therapeutic Role for Complement Inhibitors" J. Am. Soc. Nephrol. 14:S186-S191.  74. Hughes, B.J. et al. (November 15, 1989). "Monocional Antibody Targeting of Liposomes to Mouse Lung in Vivo." Cancer Research 49(2):5214-6220.  75. Humblet, C. et al. (1993). "3D Database Searching and Docking Strategies" Chapter 29 In Trojocs in Drug Design and Discovery" Section Vin Animal Reports in Medical Chemistry, Bristol, J.A. et al. eds., Academic Press, Inc.: San Diego, CA, 28:275-283.  76. International Search Report mailed September 15, 2004, for PCT Application No. PCT/US03/36459 filed November 13, 2003, three pages.  77. Jozz, M. et al. (2004). "Attachment of the Soluble Complement Regulator Factor H to Cell and Tissue Surfaces: Relevance for Pathology," Histol. Histogethol. 19:251-258.  78. Kalli, K.R. et al. (2004). "Attachment of the Soluble Complement Regulator Factor H to Cell and Tissue Surfaces: Relevance for Pathology," Histol. Histogethol. 19:251-258.  80.	66.		
Receptors, "Ann. Rev. Immunol. 18:709-737.  69. Higgins, P.J. et al. (March 1s.) 1997. "A Souble Chimeric Complement Inhibitory Protein That Possesses Both Decay-Accelerating and Factor I Cofactor Activities," J. Immunol. 158(6):2872-2881.  70. Holers, V.M. (1989). "Complement Receptors" in The Year In Immunoloay 1988, Cellular, Molecular and Cinical Aspects, Cruse J.M. et al. eds., Basel, Kanger, 4:231-240.  71. Holers, V.M. (1989). "Complement Receptors" in The Year In Immunoloay 1988, Cellular, Molecular and Cinical Aspects, Cruse J.M. et al. eds., Basel, Kanger, 4:231-240.  71. Horneister, J.W. et al. (February 1, 1993). "Soluble Complement Receptor Type 1 Prevents Human Complement-Mediated Damage of the Rabbit Isolated Heart," J. Immunol. 150(3):1055-1064.  72. Hori, Y. et al. (December 1999). "Crry, a Complement Repulatory Protein, Modulates Renal Interstitial Disease Induced by Proteinuria," Kidney Int., 55(6):2096-2106.  73. Hau, S.I.H. et al. (2003). "Chonic Progression of Tubulointerstitial Damage in Proteinuric Renal Disease Is Mediated by Complement Activation: A Therapeutic Role for Complement Inhibitors" J. Am. Soc. Nephrol. 14:S186-S191.  74. Hughes, B.J. et al. (November 15, 1989). "Monoclonal Antibody Targeting of Liposomes to Mouse Lung in Vivo." Cancer Research 49(22):5214-6220.  75. Humblet, C. et al. (1993). "3D Database Searching and Docking Strategies" Chapter 29 In Trojocs in Drug Design and Discovery" Section Vin Animal Reports in Medicinal Chemistry, Bristol, J.A. et al. eds., Academic Press, Inc.: San Diego, CA, 28:275-281.  76. International Search Report mailed September 15, 2004, for CTApplication No. PCTUL003/36459 filed November 13, 2003, three pages.  77. Jozs, M. et al. (1094). "Attachment of the Soluble Complement Regulator Factor H to Cell and Tissue Surfaces: Relevance for Pathology," Histol. Histopathol. 19:251-258.  78. Kali, K.R. et al. (2094). "Internation of Cab With Recombinant Isotypic and Chimeric Forms of CR2," J. Immunol. 147(2):590-594.  89. Koski, C.L. et al. (Ju	67.		
Possesses Both Decay-Accelerating and Factor I Cofactor Activities," J. Immunol. 158(6):2872-2881.  70. Holers, V.M. (1989). "Complement Receptors" in The Year In Immunology 1988, Cellular, Molecular and Clinical Aspects, Cruse J.M. et al. eds., Basel, Kanger, 4:231-240.  71. Hornester, J.W. et al. (February 1, 1993). "Soluble Complement Receptor Type 1 Prevents Human Complement-Mediated Damage of the Rabbit Isolated Heart," J. Immunol. 150(3):1055-1064.  72. Horl, Y. et al. (December 1999). "Crry, a Complement Requilatory Protein, Modulates Renal Interetitial Disease Induced by Proteinuria," Kidney Im. 55(6):2096-2106.  73. Hau, S.H.H. et al. (2003). "Chronic Progression of Tubulointerstial Damage in Proteinuric Renal Disease Is Mediated by Complement Activation: A Therapeutic Role for Complement Inhibitors" J. Am. Soc. Nephrol. 14:S186-S191.  74. Hughes, B.J. et al. (November 15, 1989). "Monoclonal Antibody Targeting of Liposomes to Mouse Lung in Vivo." Cancer Research 49(22):E14-6220.  75. Humblet, C. et al. (1993). "3D Database Searching and Docking Strategies" Chapter 29 In Trojocs in Drug Design and Discovery" Section Vin Animal Reports in Medicinal Chemistry, Bristol, J.A. et al. eds., Academic Press, Inc.: San Diego, CA, 28:275-283.  76. International Search Report mailed September 15, 2004, for PCT Application No. PCT/US03/36459 filed November 13, 2003, three pages.  77. Józsi, M. et al. (2004). "Natachment of the Soluble Complement Regulator Factor H to Cell and Tissue Surfaces: Relevance for Pathology," Histol. Histopathol. 19:251-258.  78. Kalli, K.R. et al. (July 15, 1991). "Interaction of IGS bit Min Recombisant Isotypic and Chimeric Forms of CR2," J. Immunol. 147(2):590-594.  79. Kaplan, M. (2004). "Culicizumah Alexion," Curr. Opin. Investig. Drugs 3(7):1017-1023.  80. Khurana, S. et al. (June 1983). "Cytoyisa of Nucleated Cells by Complement Cell Death Displays Multi-th Characteristics," Proc. Natl. Acad. Sci. USA 80(12);3816-3820.  81. Kiein, R.J. et al. (Loue 16):0000, "Complement Factor H Pol	68.		
Molecular and Clinical Aspects, Cruse, J.M. et al. eds., Basel, Karger, 4:231-240.  71. Horneister, J.W. et al. (February 1, 1993.) "Soluble Complement Receptor Type 1 Prevents Human Complement-Mediated Damage of the Rabbit Isolated Heart," J. Immunol. 150(3):1055-1064.  72. Hori, Y. et al. (December 1999), "Crry, a Complement Regulatory Protein, Modulates Renal Immerstitial Disease Induced by Proteinuriar," Kindroy Int. 56(9):2096-2108.  73. Heu, S.H. et al. (2003) "Chronic Progression of Tubulcinterstitial Damage in Proteinuriar (American) Report of the Report of	69.	Possesses Both Decay-Accelerating and Factor I Cofactor Activities," J. Immunol.	
Human Complement-Mediated Damage of the Rabbit Isolated Heart, "J. Immunol. 150(3):1055-1064.  72. Hori, Y. et al. (December 1999). "Crry, a Complement Regulatory Protein, Modulates Renal Interstitial Disease Induced by Proteinuria," <i>Kidney Int.</i> 56(6):2906-2108.  73. Hau, S.I.H. et al. (2003). "Chronic Progression of Tubulointerstitial Damage in Proteinuria Renal Disease is Mediated by Complement Activation: A Therapeutic Role for Complement Inhibitors?" <i>J. Am. Soc. Nephrol.</i> 14:S186-S191.  74. Hughes, B.J. et al. (November 15, 1989). "Monoclonal Antibody Targeting of Liposomes to Mouse Lung <i>in Vivo</i> ," Cancer Research 49(22):6214-6220.  75. Humblet, C. et al. (1993). "30 Database Searching and Docking Strategies" Chapter 29 in Topics in Drug Design and Discovery' Section VI In Animal Reports in Medicinal Chemistry. Bristol. J.A. et al. eds., Academic Press, Inc.: San Diego, CA. 282/35-283.  76. International Search Report mailed September 15, 2004, for PCT Application No. PCTUS03/34699 filed November 13, 2003, three pages.  77. Jözs, M. et al. (2004). "Attachment of the Soluble Complement Regulator Factor H to Cell and Tissue Surfaces: Relevance for Pathology," <i>Histol. Histopathol.</i> 19:251-258.  78. Kalli, K.R. et al. (July 15, 1991). "Interaction of Ica3 With Recombinant Isotypic and Chimeric Forms of CR2," <i>J. Immunol.</i> 147(2):390-594.  79. Kaplan, M. (2002). "Eculizumab Alexion," <i>Curr. Opin. Investig. Drugs</i> 3(7):1017-1023.  80. Khurana, S. et al. (June 9, 1998). "Crystal Structure of 2,5-direbro-gluconic Acid Reductase A Complexed with NADPH at 21. A Resolution," <i>Proc. Natl. Acad. Sci.</i> 195(15):768-8-0773.  81. Kiein, R.J. et al. (April 15, 2005). "Complement Factor H Polymorphism in Age-Related Macular Degeneration," <i>Sciences</i> , <i>Proc. Natl. Acad. Sci.</i> 5(15):768-8-6773.  82. Koski, C.L. et al. (June 1983). "Cryotysis of Nucleated Cells by Complement: Cell Death Displays Multi-Int Characteristics," <i>Proc. Natl. Acad. Sci.</i> 054, 80(12):3816-3820.  83. Kroshus, T.J. et al. (December 15, 1995). "Comple	70.		
Interstitial Disease Induced by Proteinuria, "Kidney Int., 56(6):2096-2106.  73. Hau, S.I.H. et al. (2003). "Chorolic Progression of Tubulointerstitial Damage in Proteinuric Renal Disease Is Mediated by Complement Activation: A Therapeutic Role for Complement Inhibitors" J. Am. Soc. Nephrol. 14:S186-S191.  74. Hughes, B.J. et al. (November 15, 1989). "Monoclonal Antibody Targeting of Liposomes to Mouse Lung In Vivo." Cancer Research 49(22):6214-6220.  75. Humblet, C. et al. (1993). "3D Database Searching and Docking Strategies" Chapter 29 In Trojics in Drug Design and Discovery" Section VI In Animal Reports in Medicinal Chemistry, Bristol, J.A. et al. eds., Academic Press, Inc. San Diego, CA, 28:275-283.  76. International Search Report mailed September 15, 2004, for PCT Application No. PCT/US03/36459 filed November 13, 2003, three pages.  77. Jozs, M. et al. (2004). "Natachment of the Soluble Complement Regulator Factor H to Cell and Tissue Surfaces: Relevance for Pathology," Histol. Histopathol. 19:251-258.  78. Kalli, K.R. et al. (July 15, 1991). "Interaction of Ic3b With Recombinant Isotypic and Chimeric Forms of CR2," J. Immunol. 147(2):590-594.  79. Kaplan, M. (2002). "Eculizumah Alexion," Curr. Opin. Investig. Drugs 3(7):1017-1023.  80. Khurana, S. et al. (June 9, 1998). "Crystal Structure of 2,5-diketo-o-gluconic Acid Reductase A Complexed with NADPH at 2,1-A Resolution." Proc. Natl. Acad. Sci. 9(5)(2):6788-8773.  81. Kiein, R.J. et al. (April 15, 2005). "Complement Factor H Polymorphism in Age-Related Macular Degeneration," Science, Proc. Natl. Acad. Sci. USA 80(12):3816-3820.  82. Koski, C.L. et al. (June 1983). "Crystal Structure of 2,6-diketo-o-gluconic Acid Reductase A Complexed with Characteristics," Proc. Natl. Acad. Sci. USA 80(12):3816-3820.  83. Kroshus, T.J. et al. (December 15, 1995). "Complement Inhibition with an Anti-C5 Monoclonal Antibody Prevents Acute Cardiac Tissue Injury in an Ex Vivo Model of Pig-To-Human Heart Transplantation." "Transplantation 69(11):2282.	71.	Human Complement-Mediated Damage of the Rabbit Isolated Heart," J. Immunol. 150(3):1055-1064.	_
Renat Disease Is Mediated by Complement Activation: A Therapeutic Role for Complement Inhibitors" J. Am. Soc. Nephrol. 14:S186-S191.  74. Hughes, B.J. et al. (November 15, 1989). "Monoclonal Antibody Targeting of Liposomes to Mouse Lung In Vivo." Cancer Research 49(22):5214-6220.  75. Humblet, C. et al. (1993). "3D Database Searching and Docking Strategies" Chapter 29 In Trojocs in Drug Design and Discovery" Section VI In Animal Reports in Medicinal Chemistry, Bristol, J.A. et al. eds., Academic Press, Inc. San Diego, CA, 28:275-283.  76. International Search Report mailed September 15, 2004, for PCT-Application No. PCT/US03/36459 filed November 13, 2003, three pages.  77. Jozs, M. et al. (2004). "Natachment of the Soluble Complement Regulator Factor H to Cell and Tissue Surfaces: Relevance for Pathology," Histol. Histopathol. 19:251-258.  78. Kalli, K.R. et al. (July 15, 1991). "Interaction of Ic3b With Recombinant Isotypic and Chimeric Forms of CR2," J. Immunol. 147(2):590-594.  79. Kaplan, M. (2002). "Eculizumah Alexion," Curr. Opin. Investig. Drugs 3(7):1017-1023.  80. Khurana, S. et al. (June 9, 1998). "Crystal Structure of 2,5-diketo-o-gluconic Acid Reductase A Complexed with NADPH at 2,1-A Resolution," Proc. Natl. Acad. Sci. 9(5)(2):578-86-773.  81. Klein, R.J. et al. (April 15, 2005). "Complement Factor H Polymorphism in Age-Related Macular Degeneration," Science, 2006(72):3816-3836.  82. Koski, C.L. et al. (June 1983). "Cryptais of Nucleated Cells by Complement: Cell Death Displays Multi-thic Characteristics," Proc. Natl. Acad. Sci. USA 80(2):3816-382.  83. Kroshus, T.J. et al. (December 15, 1995). "Complement Inhibition with an Anti-C5 Monoclonal Antibody Prevents Acute Cardiac Tissue Injury in an Ex Vivo Model of Pig-To-Human Heart Transplantation," Transplantation 69(11):2282-2298.  84. Kroshus, T.J. et al. (June 15). 2000. "A Recombinant Soluble Chimeric Complement Inhibitor Composed of Human CD46 and CD55 Reduces Acute Cardiac Tissue Injury in Models of Pig-to-Human Heart Transplantation," Transpl	72.	Interstitial Disease Induced by Proteinuria," Kidney Int. 56(6):2096-2106.	
Mouse Lung in Vivo, "Cancer Research 49(22):6214-6220.  75. Humblel, C. et al. (1993). 310 Database Searching and Docking Strategies" Chapter 29 In Topics in Drug Design and Discovery, Section VI In Animal Reports in Medicinal Chemistry, Bristol, J.A. et al. eds., Academic Press, Inc., San Diego, CA, 282/35-283.  76. International Search Report mailed September 15, 2004, for PCT Application No. PCT/US0/336495 filed November 13, 2003, three pages.  77. Józsi, M. et al. (2004). "Attachment of the Soluble Complement Regulator Factor H to Cell and Tissue Surfaces: Relevance for Pathology," "Ristor Histopathon," 19:251-258.  78. Kalli, K.R. et al. (July 15, 1991). "Interaction of IC3b With Recombinant Isotypic and Chimeric Forms of ICR2", J. Immunol. 147(2):590-594.  79. Kaplan, M. (2002). "Eculizumab Alexion," Curr. Opin. Investig. Drugs 3(7):1017-1023.  80. Knurana, S. et al. (June 9, 1998). "Orystal Structure of 2,5-dixeb-o-gluconic Acid Reductase A Complexed with NADPH at 21. A Resolution," "Proc. Natl. Acad. 55. 95(12):678-86773.  81. Klein, R.J. et al. (April 15, 2005). "Complement Factor H Polymorphism in Age-Related Macular Degeneration," Science, 300(6720):385-398.  82. Koski, C.L. et al. (June 1983). "Cytolysis of Nucleated Cells by Complement: Cell Death Displays Multi-frich Characteristics," Proc. Natl. Acad. Sci. USA 80(12):3816-3820.  83. Kroshus, T.J. et al. (December 15, 1995). "Complement Inhibition with an Anti-C5 Monoclonal Antibody Prevents Acute Cardiac Tissue Injury in an Ex Vivo Model of Pig-To-Luman Xenotransplantation," Transplantation 60(11):1194-1202.  84. Kroshus, T.J. et al. (June 1985). "Mapping of the C3d Receptor (CR2)-Binding Site and a Necesaries in the C3d Domain of the Third Component of Complement," Proc. Natl. Acad. Sci. USA 82(12):4235-4239.  85. Lambris, J.D. et al. (June 1980). "Mapping of the C3d-Receptor (CR2)-Binding Site and a Necesaries in Section of Complement," Proc. Natl. Acad. Sci. USA 82(12):4235-4239.	73.	Renal Disease Is Mediated by Complement Activation: A Therapeutic Role for Complement	
Topics in Drug Design and Discovery' Section Vi In Animal Reports in Medicinal Chemistry. Bristol, J.A. et al. eds., Academic Press, Inc.: San Diego, CA, 282/35-283.  76. International Search Report mailed September 15, 2004, for PCT Application No. PCT/US0/336495 filed November 13, 2003, three pages.  77. Júzsi, M. et al. (2004). "Attachment of the Soluble Complement Regulator Factor H to Cell and Tissue Surfaces: Relevance for Pathology." "Histor, Histopathol. 19:251-258.  78. Kalli, K.R. et al. (July 15, 1991). "Interaction of IC3b With Recombinant Isotypic and Chimeric Forms of ICR2". J. Immunol. 1472;595-084.  79. Kaplan, M. (2002). "Eculizumab Alexion," Curr. Opin. Investig. Drugs 3(7):1017-1023.  80. Knurana, S. et al. (June 9, 1998). "Oystal Structure of 2,5-directo-g-luconic Acid Reductase A Complexed with NADPH at 2.1-A Resolution." "Proc. Natl. Acad. Sci. 95(12):578-6773.  81. Klein, R.J. et al. (April 15, 2005). "Complement Factor H Polymorphism in Age-Related Macular Degeneration," Science 308(6720):385-389.  82. Koski, C.L. et al. (June 1983). "Cytolysis of Nucleated Cells by Complement: Cell Death Displays Multi-Int Characteristics," Proc. Natl. Acad. Sci. USA 80(12):3816-3820.  83. Kroshus, T.J. et al. (December 15, 1995). "Complement Inhibition with an Anti-C5 Monoclonal Antibody Prevents Acute Cardiac Tissue Injury in an Ex Vivo Model of Pig-To-Human Kenotransplantation," Transplantation 80(11):1194-1202.  84. Kroshus, T.J. et al. (June 15, 2000). "A Recombinant Soluble Chimeric Complement Inhibitor Composed of Human CD46 and CD55 Reduces Acute Cardiac Tissue Injury in Models of Pig-to-Human Heart Transplantation," Transplantation 60(11):2282-2289.  85. Lambris, J.D. et al. (June 1900). "Animan of Complement Complement," Proc. Natl. Acad. Sci. USA 82(12):4235-4239.  86. Lambris, J.D. et al. (June 1900). "Animan of Complement Complement," Proc. Natl. Acad. Sci. USA 82(12):4235-4239.	74.		
PCT/US0/3/36495 filed November 13, 2003, three pages.  77. Józsi, M. et al. (2004). *Natschment of the Soluble Complement Regulator Factor H to Cell and Tissue Surfaces: Relevance for Pathology, "Histol. Histopathol. 19:251-258.  78. Kalli, K.R. et al. (July 15, 1991). "Interaction of IGSb With Recombinant Isotypic and Chimeric Forms of CR2," J. Immunol. 147(2):590-594.  79. Kaplan, M. (2002). "Eculizumah Alexion," Curr. Opin. Investig. Drugs 3(7):1017-1023.  80. Khurana, S. et al. (June 9, 1998). "Crystal Structure of 2,5-diketo-o-gluconic Acid Reductase A Complexed with NADPH at 21A Resolution," Proc. Natl. Acad. Sci. 95(12):8768-8773.  81. Klein, R.J. et al. (April 15, 2005). "Complement Factor H Polymorphism in Age-Related Macular Degeneration," Science, 308(5720):885-389.  82. Koski, C. L. et al. (June 1983). "Crytolysis of Nucleated Cells by Complement: Cell Death Displays Multi-thic Characteristics," Proc. Natl. Acad. Sci. USA 80(12):3816-3820.  83. Kroshus, T.J. et al. (December 15, 1995). "Complement Inhibition with an Ami-C5 Monoclonal Antibody Prevents Acute Cardiac Tissue Injury in an Ex Vivo Model of Pig-To-Human Mart Transplantation (2000). "A Recombinant Soluble Chimeric Complement Inhibitor Composed of Human CD46 and CD55 Reduces Acute Cardiac Tissue Injury in Models of Pig-to-Human Heart Transplantation," "Transplantation 69(11):2282-2289.  85. Lambris, J.D. et al. (June 1985). "Mapping of the C30 Receptor (CR2)-Binding Site and a Necoantigenic Site in the C33 Domain of the Third Component of Complement," Proc. Natl. Acad. Sci. USA 82(12):4235-4239.  86. Lambris, J.D. et al. (June 1980). "Acidion of the C30-Inactivator on Cell-Bound C30," J. Immunol.	75.	"Topics in Drug Design and Discovery" Section VI In Animal Reports in Medicinal Chemistry,	
77. Józsi, M. et al. (2004). "Attachment of the Soluble Complement Regulator Factor H to Cell and Tissue Surfaces: Relevance for Pathology," "Histor. Histograthol. 19:251-258.  78. Kalli, K.R. et al. (July 15, 1991). "Interaction of IC3b With Recombinant Isotypic and Chimeric Forms of CR2; "J. Immunol. 147(2):950-954.  79. Kaplan, M. (2002). "Eculizumab Alexion," Curr. Opin. Investig. Drugs. 3(7):1017-1023.  80. Khurana, S. et al. (June 9, 1998). "Crystal Structure of 2,5-directo-gluconic Acid Reductase A Complexed with NADPH at 2.1-A Resolution," Proc. Natl. Acad. Sci. 95(12):6768-6773.  81. Kiein, R.J. et al. (April 15, 2005). "Complement Factor H Polymorphism in Age-Related Macular Degeneration," Science 308(5720):385-399.  82. Koski, C.L. et al. (June 1983). "Cytolysis of Nucleated Cells by Complement: Cell Death Displays Multi-Int Characteristics," Proc. Natl. Acad. Sci. USA 80(12):3816-3820.  83. Kroshus, T.J. et al. (December 15, 1995). "Complement Inhibition with an Anti-C5 Monoclonal Antibody Prevents Acute Cardiac Tissue Injury in an Ex Vivo Model of Pig-To-Human Xenotransplantation," Transplantation 80(11):1194-1202.  84. Kroshus, T.J. et al. (June 15, 2000). "A Recombinant Soluble Chimeric Complement Inhibitor Composed of Human CD46 and CD55 Reduces Acute Cardiac Tissue Injury in Models of Pig-to-Human Heart Transplantation," Transplantation 69(11):2282-2289.  85. Lambris, J.D. et al. (June 1985). "Mapping of the C3d Receptor (CR2)-Binding Site and a Necesatigenic Site in the C3d Domain of the Third Component of Complement," Proc. Natl. Acad. Sci. USA 82(12):4235-4239.  86. Law S.K. et al. (March 1979). "Acision of the C3d-Inactivator on Cell-Bound C3b," J. Immunol.	76.	International Search Report mailed September 15, 2004, for PCT Application No.	
Forms of CR2,** J. Immunol. 147(2):590-594.  79. Kaplan, M. (2002). "Eculizumab Alexion," Curr. Opin. Investig. Drugs 3(7):1017-1023.  80. Khurana, S. et al. (June 9, 1998). "Crystal Structure of 2,5-diketo-o-gluconic Acid Reductase A Complexed with NADPH at 21-14 Resolution," Proc. Natl. Acad. Sci. 95(12):678-8-073.  81. Klein, R.J. et al. (April 15, 2005). "Complement Factor I Polymorphism in Age-Related Macular Degeneration," Science, 308(5720):885-389.  82. Koski, C.L. et al. (June 1983). "Cytolysis of Nucleated Cells by Complement: Cell Death Displays Multi-hit Characteristics," Proc. Natl. Acad. Sci. USA 80(12):3816-3820.  83. Kroshus, T.J. et al. (December 15, 1995). "Complement Inhibition with an Anti-C5 Monoclonal Antibody Prevents Acute Cardiac Tissue Injury in an Ex Vivo Model of Pig-To-Human Xenotransplantation," "Transplantation 60(11):2192-2298.  84. Kroshus, T.J. et al. (June 15, 2000). "A Recombinant Soluble Chimeric Complement Inhibitor Composed of Human CD46 and CD55 Reduces Acute Cardiac Tissue Injury in Models of Pig-to-Human Heart Transplantation," "Transplantation 60(11):2292-2298.  85. Lambris, J.D. et al. (June 1985). "Mapping of the C3d Receptor (CR2)-Binding Site and a Necoantigenic Site in the C3d Domain of the Third Component of Complement," Proc. Natl. Acad. Sci. USA 82(12):4235-4239.  86. Law S.K. et al. (March 1979). "Acision of the C3b-Inactivator on Cell-Bound C3b," J. Immunol.	77.	Józsi, M. et al. (2004). "Attachment of the Soluble Complement Regulator Factor H to Cell and Tissue Surfaces: Relevance for Pathology," <i>Histol. Histopathol.</i> 19:251-258.	
80. Khurana, S. et al. (June 9, 1998). "Crystal Structure of 2,5-diketo-o-gluconic Acid Reductase A Complexed with NADPH at 2.1-A Resolution." Proc. Natl. Acad. Sci. 95(12):6788-8773.  81. Klein, R.J. et al. (April 15, 2005). "Complement Factor I Polymorphism in Age-Related Macular Degeneration." Science 309(6720):885-389.  82. Koski, C.L. et al. (June 1983). "Cytolysis of Nucleated Cells by Complement: Cell Death Displays Multi-Hich Characteristics." Proc. Natl. Acad. Sci. USA 80(12):3816-3820.  83. Kroshus, T.J. et al. (December 15, 1995). "Complement Inhibition with an Anti-C5 Monoclonal Antibody Prevents Acute Cardiac Tissue Injury in an Ex Vivo Model of Pig-To-Human Xenotransplantation," "Transplantation 80(11):1194-1202.  84. Kroshus, T.J. et al. (June 15, 2000). "A Recombinant Soluble Chimeric Complement Inhibitor Composed of Human CD46 and CD55 Reduces Acute Cardiac Tissue Injury in Models of Pig-to-Human Heart Transplantation," "Transplantation 60(11):2282-2289.  85. Lambris, J.D. et al. (June 1985). "Mapping of the C3d Receptor (CR2)-Binding Site and a Necoantigenic Site in the C3d Domain of the Third Component of Complement," Proc. Natl. Acad. Sci. USA 82(12):4235-4239.  86. Law, S.K. et al. (March 1979). "Acision of the C3b-Inactivator on Cell-Bound C3b," J. Immunol.	78.	Kalli, K.R. et al. (July 15, 1991). "Interaction of iC3b With Recombinant Isotypic and Chimeric Forms of CR2," <i>J. Immunol.</i> 147(2):590-594.	
80. Khurana, S. et al. (June 9, 1998). "Crystal Structure of 2,5-diketo-o-gluconic Acid Reductase A Complexed with NADPH at 2.1-A Resolution." Proc. Natl. Acad. Sci. 95(12):6788-8773.  81. Klein, R.J. et al. (April 15, 2005). "Complement Factor I Polymorphism in Age-Related Macular Degeneration." Science 309(6720):885-389.  82. Koski, C.L. et al. (June 1983). "Cytolysis of Nucleated Cells by Complement: Cell Death Displays Multi-Hich Characteristics." Proc. Natl. Acad. Sci. USA 80(12):3816-3820.  83. Kroshus, T.J. et al. (December 15, 1995). "Complement Inhibition with an Anti-C5 Monoclonal Antibody Prevents Acute Cardiac Tissue Injury in an Ex Vivo Model of Pig-To-Human Xenotransplantation," "Transplantation 80(11):1194-1202.  84. Kroshus, T.J. et al. (June 15, 2000). "A Recombinant Soluble Chimeric Complement Inhibitor Composed of Human CD46 and CD55 Reduces Acute Cardiac Tissue Injury in Models of Pig-to-Human Heart Transplantation," "Transplantation 60(11):2282-2289.  85. Lambris, J.D. et al. (June 1985). "Mapping of the C3d Receptor (CR2)-Binding Site and a Necoantigenic Site in the C3d Domain of the Third Component of Complement," Proc. Natl. Acad. Sci. USA 82(12):4235-4239.  86. Law, S.K. et al. (March 1979). "Acision of the C3b-Inactivator on Cell-Bound C3b," J. Immunol.	 79.	Kaplan, M. (2002), "Eculizumab Alexion," Curr. Opin. Investig. Drugs 3(7):1017-1023	
81. Klein, R.J. et al. (April 15, 2005). "Complement Factor H Polymorphism in Age-Related Macular Degeneration," Science, 308(5720):385-389.  82. Koski, C.L. et al. (June 1983). "Cytolysis of Nucleated Cells by Complement: Cell Death Displays Multi-Hich Characteristics," Proc. Natl. Acad. Sci. USA 80(12):3816-3820.  83. Kroshus, T.J. et al. (December 15, 1995). "Complement Inhibition with an Anti-C5 Monocional Antibody Prevents Acute Cardiac Tissue Injury in an Ex Vivo Model of Pig-To-Human Xenotransplantation," "Transplantation 80(11):1194-1202.  84. Kroshus, T.J. et al. (June 15, 2000). "A Recombinant Soluble Chimeric Complement Inhibitor Composed of Human CD46 and CD55 Reduces Acute Cardiac Tissue Injury in Models of Pig-to-Human Heart Transplantation," "Transplantation 60(11):2282-2289.  85. Lambris, J.D. et al. (June 1985). "Mapping of the C3d Receptor (CR2)-Binding Site and a Necoantigenic Site in the C3d Domain of the Third Component of Complement," Proc. Natl. Acad. Sci. USA 82(12):4235-4239.  86. Law, S.K. et al. (March 1979). "Acision of the C3b-Inactivator on Cell-Bound C3b," J. Immunol.	80.	Khurana, S. et al. (June 9, 1998). "Crystal Structure of 2,5-diketo-p-gluconic Acid Reductase A	
Displays Multi-hit Characteristics," Proc. Natl. Acad. Sci. USA 80(12):3816-3820.  83. Kroshus, T. J. et al. (December 15, 1995). "Complement Inhibition with an Anti-CS Monoclonal Antibody Prevents Acute Cardiac Tissue Injury in an Ex Vivo Model of Pig-To-Human Xanotransplantation," Transplantation 80(11):1194-1202.  84. Kroshus, T. J. et al. (June 15, 2000). "A Recombinant Soluble Chimeric Complement Inhibitor Composed of Human CD46 and CD55 Reduces Acute Cardiac Tissue Injury in Models of Pigito-Human Heart Transplantation," Transplantation 89(11):2282-2289. Inding Isle and a Necentified Site in the C3d Domain of the Third Complement Ocomplement," Proc. Natl. Acad. Sci. USA 82(12):4235-4239.  85. Law S. K. et al. (March 1979). "Acision of the C3b-Inactivator on Cell-Bound C3b," J. Immunol.	81.	Klein, R.J. et al. (April 15, 2005). "Complement Factor H Polymorphism in Age-Related	
83. Kroshus, T.J. et al. (December 15, 1995). "Complement Inhibition with an Anti-C5 Monoclonal Anthody Prevente Acute Cardiact Tissue Injury in an Ex Vivo Model of Pig-To-Human Xenotransplantation," <i>Transplantation</i> 60(11):1194-1202.  84. Kroshus, T.J. et al. (June 15, 2000). "A Recombinant Soluble Chimeric Complement Inhibitor Composed of Human CD46 and CD55 Reduces Acute Cardiac Tissue Injury in Models of Pig-to-Human Heart Transplantation," <i>Transplantation</i> 69(11):2282-2299.  85. Lambris, J.D. et al. (June 1985). "Mapping of the C3d Receptor (CR2)-Binding Site and a Necoantigenic Site in the C3d Domain of the Third Component of Complement," <i>Proc. Natl. Acad. Sci. USA</i> 82(12):4235-4239.  86. Law, S.K. et al. (March 1979). "Acision of the C3b-Inactivator on Cell-Bound C3b," <i>J. Immunol.</i>	82.		
84. Kroshus, T.J. et al. (June 15, 2000). "A Recombinant Soluble Chimenic Complement Inhibitor Composed of Human CD46 and CD56 Reduces Acute Cardiac Tissue Injury in Models of Piglot-Human Heart Transplantation," Transplantation 69(11):2282-2289.  85. Lambris, J.D. et al. (June 1985). "Mapping of the C3d Receptor (CR2)-Binding Site and a Neoentigenic Site in the C3d Domain of the Third Component of Complement," Proc. Natl. Acad. Sol. USA 82(12):4235-4239.  86. Law, S.K. et al. (March 1979). "Action of the C3b-Inactivator on Cell-Bound C3b," J. Immunol.	83.	Kroshus, T.J. et al. (December 15, 1995). "Complement Inhibition with an Anti-C5 Monoclonal Antibody Prevents Acute Cardiac Tissue Injury in an Ex Vivo Model of Pig-To-Human	
Lambris, J.D. et al. (June 1985). "Mapping of the C3d Receptor (CR2)-Binding Site and a Neoantigenic Site in the C3d Domain of the Third Component of Complement," Proc. Natl. Acad. Sci. USA 82(12):4235-4239.      Law, S.K. et al. (March 1979). "Action of the C3b-Inactivator on Cell-Bound C3b," J. Immunol.	84.	Kroshus, T.J. et al. (June 15, 2000). "A Recombinant Soluble Chimeric Complement Inhibitor Composed of Human CD46 and CD56 Reduces Acute Cardiac Tissue Injury in Models of Pig- to-Human Heart Transplantation," <i>Transplantation</i> 69(11):2282-2289.	
86. Law, S.K. et al. (March 1979). "Action of the C3b-Inactivator on Cell-Bound C3b," J. Immunol.	85.	Lambris, J.D. et al. (June 1985). "Mapping of the C3d Receptor (CR2)-Binding Site and a Neoantigenic Site in the C3d Domain of the Third Component of Complement," <i>Proc. Natl. Acad. Sci. USA</i> 82(12):4235-4239.	
	86.	Law, S.K. et al. (March 1979). "Action of the C3b-Inactivator on Cell-Bound C3b," J. Immunol.	

Examiner Date	
ISignature I	
4140004	

0	stitute for form 1449/PTO			Complete if Known		
Sut	islitute for form 1449/PTO			Application Number	10/534,772	
I IN	FORMATION	ı DI	SCLOSURE	Filing Date	(Int'l.) November 13, 2003	
	TATEMENT E			First Named Inventor	Stephen TOMLINSON	
Ĭ	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Art Unit	1653	
	(Use as many she	ets as	necess ary)	Examiner Name	Not Yet Assigned	
Sheet	5	of	8	Attorney Docket Number	577712000200	

87.	Law, S.K.A. et al. (1995). "Complement" In In Focus, Second Edition, Male, D. ed., IRL Press at Oxford University Press, Inc.: New York, NY, pp. vii - ix (Table of Contents Only.)	
88.	Linton, S.M. et al. (November 2000). "Therapeutic Efficacy of a Novel Membrane-Targeted Complement Regulator in Antigen-Induced Arthritis in the Rat," <i>Arthritis Rheum.</i> 43(11):2590-2597.	
89.	Litzinger, D.C. et al. (1992). "Biodistribution and Immunotargetability of Ganglioside-Stabilized Dioleoylphosphatidylethanolamine Liposomes," <i>Biochimica et Biophysica Acta</i> . 1104:179-187.	
90.	Lowell, C.A. et al. (December 1, 1989). "Mapping of the Epstein-Barr Virus and C3dg Binding Sites to a Common Domain on Complement Receptor Type 2," <i>J. Exp. Med.</i> 170(6):1931-1946.	
91.	Martin, D.R. et al. (December 1991). "Determination of the Structural Basis for Selective Binding of Epstein-Barr Virus to Human Complement Receptor Type 2," J. Exp. Med. 174:1299-1311.	
92.	Martin, D.R. et al. (August 1994). "Determination of the Role for CD21 During Epstein-Barr Virus Infection of B-Lymphoblastoid Cells," <i>J. Virol.</i> 68(8):4716-4726.	
93.	Matsumoto, A.K. et al. (January 1,1991). "Intersection of the Complement and Immune Systems: A Signal Transduction Complex of the B Lymphocyte-Containing Complement Receptor Type 2 and CD19," J. Exp. Med. 173(1):55-54.	
94.	Mendrick, D.L. et al. (1983). "Monoclonal Antibodies Against Rat Glomerular Antigens: Production and Specificity," <i>Laboratory Investigation</i> 49(1):107-117.	
95.	Mendrick, D.L. et al. (1988). "I. Induction of Proteinuria in the Rat by a Monoclonal Antibody Against SGP-115/107," Kidney Int. 33:818-830.	
96.	Meri, S. et al. (June 15, 1996). "Structural Composition and Functional Characterization of Soluble CD59: Heterogeneity of the Oligosaccharide and Glycophosphoinositol (GPI) Anchor Revealed by Laser-Desorption Mass Spectrometric Analysis," <i>Biochem J.</i> 316(Pt.3):923-935.	
97.	Moir, S. et al. (September 4, 2000). "B Cells of HIV-1-Infected Patients Bind Virions Through CD21-Complement Interactions and Transmit Infectious Virus to Activated T Cells," <i>J. Exp.</i> Med. 192(5):637-645.	
98.	Molina, H. et al. (July 5, 1991). "Analysis of Epstein-Barr Virus-Binding Sites on Complement Receptor 2 (CR2/CD21) Using Human-Mouse Chimeras and Peptides," <i>J. Biol. Chem.</i> 266(19):12173-12179.	
99.	Molina, H. et al. (July 15, 1994). "Analysis of C3b/C3d Binding Sites and Factor I Cofactor Regions Within Mouse Complement Receptor 1 and 2," J. Immunol. 153(2):789-795.	
100.	Molina, H. et al. (May 15, 1995). "Characterization of a Complement Receptor 2 (CR2, CD21) Ligand Binding Site for C3," <i>J. Immunol.</i> 154(10):5426-5435.	
101.	Molina, H. et al. (April 1996). "Markedly Impaired Humoral Immune Response in Mice Deficient in Complement Receptors 1 and 2," Proc. Natl. Acad. Sci. USA 93:3357-3361.	
102.	Moran, P. et al. (September 1, 1992). "Human Recombinant Soluble Decay Accelerating Factor Inhibits Complement Activation <i>in vitro</i> and <i>in vivo</i> ," <i>J. Immunol.</i> 149(5):1736-1743.	
103.	Morgan, B.P. (April 1994). "Clinical Complementology: Recent Progress and Future Trends," Eur. J. Clin. Invest. 24(4):219-228.	
104.	Müller-Eberhard, H.J. (1988). "Molecular Organization and Function of the Complement System," Ann. Rev. Biochem. 57:321-347.	
105.	Mulligan, M.S. et al. (April 15, 1999). "Endothelial Targeting and Enhanced Antiinflammatory Effects of Complement Inhibitors Possessing Siatyl Lewis" Moieties," <i>J. Immunol.</i> 162(8):4952-4959.	
106.	Nagar, B. et al. (May 22, 1998). "X-Ray Crystal Structure of C3d: A C3 Fragment and Ligand for Complement Receptor 2," Scianco 280:1277-1281.	
107.	Okano, M. (January 1998). "Epstein-Barr Virus Infection and its Role in the Expanding Spectrum of Human Diseases," Acta Paediatr. 87:11-18.	

Examiner	Date	
Signature	Considered	

0.1.12.1	e for form 1449/P	TO.		Complete if Known		
Substitut	e for form 1449/P	10		Application Number	10/534,772	
INF	ORMATIC	ON DISC	LOSURE	Filing Date	(Int'l.) November 13, 2003	
			PLICANT	First Named Inventor	Stephen TOMLINSON	
0.,			LIGAR	Art Unit	1653	
	(Use as many	she ets as nee	ess ary)	Examiner Name	Not Yet Assigned	
Sheet	6	of	8	Attorney Docket Number	577712000200	

108.	Pietersz, G.A. et al. (1992). "Antibody Conjugates for the Treatment of Cancer," <i>Immunolog. Reviews</i> 129:57-80.	
109.	Poznansky, M.C. et al. (August 15, 1989). "The Difference Between Human C3F and C3S Results From a Single Amino Acid Change From an Asparagine to an Aspartate Residue at Position 1216 on the a-Chain of the Complement Component, C3," J. Immunol. 143(4):1254-1258.	
110.	Prodeus, A.P. et al. (November 1998). "A Critical Role for Complement in Maintenance of Self-Tolerance," <i>Immunity</i> 9(5):721-731.	
111.	Prodinger, W.M. et al. (November 1, 1998). "Characterization of C3dg Binding to a Recess Formed Between Short Consensus Repeats 1 and 2 of Complement Receptor Type 2 (CR2; CD21)," J. Immunol. 161(9):4604-4610.	
112.	Quigg, R.J. et al. (May 1, 1998). "Blockade of Antibody-Induced Glomerulonephritis with Crry- lg, a Soluble Munne Complement Inhibitor," J. Immunol. 160(9):4553-4560.	
113.	Quigg, R.J. et al. (January 2000). "Production and Functional Analysis of Rat CD59 and Chimeric CD59-Crry as Active Soluble Proteins in <i>Pichia pastoris</i> ," <i>Immunology</i> 99(1):46-53.	П
114.	Rabinovici, R. et al. (September 1, 1992). "Role of Complement in Endotoxin/Platelet- Activating Factor-Induced Lung Injury," J. Immunol. 149(5):1744-1750.	П
115.	Ramm, L.E. et al. (August 1982). "Transmembrane Channel Formation by Complement: Functional Analysis of the Number of C5b6, C7, C8, and C9 Molecules Required for a Single Channel," <i>Proc. Natl. Acad. Sci. USA</i> 79(15):4751-4755.	
116.	Rao, P.E. et al. (July 1985). "OKB7, A Monoclonal Antibody That Reacts at or Near the C3d Binding Site of Human CR2," Cell. Immunol. 93(2):549-555.	П
117.	Rinder, C.S. et al. (September 1995). "Blockade of C5a and C5b-9 Generation Inhibits Leukocyte and Platelet Activation During Extracorporeal Circulation," <i>J. Clin. Invest.</i> 96(3):1564-1572.	
118.	Rioux, P. (2001). "TP-10 AVANT Immunotherapeutics," Curr. Opin. Investig. Drugs 2:364-371.	
119.	Ritterhaus, C.W. et al. (April 16, 1999). "Recombinant Glycoproteins That Inhibit Complement Activation and Also Bind the Selectin Adhesion Molecules," J. Biol. Chem. 274(16):11267-11244.	
120.	Roffer, S.R. et al. (October 24, 1991). "Anti-Neoplastic Glucuronide Prodrug Treatment of Human Tumor Cells Targeted with a Monoclonal Antibody-Enzyme Conjugate," <i>Biochem. Pharmacol.</i> 42(10):2062-2065.	
121.	Ross, G.D. et al. (February 1992). "Macrophage Cytoskeleton Association with CR3 and CR4 Regulates Receptor Mobility and Phagocytosis of iC3b-opsonized Erythrocytes," <i>J. Leukoc. Biol.</i> 51(2):109-117.	
122.	Rothlein, R. et al. (May 1, 1986). "The Requirement for Lymphocyte Function-Associated Antigen 1 in Homotypic Leukocyte Adhesion Stimulated by Phorbol Ester," <i>J. Exp. Med.</i> 163(5):1132-1149.	
123.	Rushmere, N.K. et al. (February 2000). "Production and Functional Characterization of a Soluble Recombinant Form of Mouse CD59," Immunology 99(2):326-332.	
124.	Salerno, C.T. et al. (March 2002). "A Soluble Chimeric Inhibitor of C3 and C5 Convertases, Complement Activation Blocker-2, Prolongs Graft Survival in Pig-to-Rhesus Monkey Heart Transplantation," Xenotransplantation 9(2):125-134.	
125.	Schwarzenbacher, R. et al. (November 15, 1999). "Crystal Structure of Human β2-glycoprotein I: Implications for Phospholipid Binding and the Antiphospholipid Syndrome," <i>EMBO J.</i> 18(22):622-6239.	
126.	Senter, P.D. et al. (November/December 1991). "Generation of 5-Fluorouracil From 5- Fluorocytosine by Monoclonal Antibody-Cytosine Dearninase Conjugates," <i>Bioconjugate</i> <i>Chem.</i> 2(5):447-451.	

Examiner	Date	
Signature	Considered	
4440004	- Seriolatics	

	stitute for form 1449/PTO			Complete if Known		
Sui	isilitate for form 1449/P1O			Application Number	10/534,772	
11	FORMATIO	N DI	SCLOSURE	Filing Date	(Int'l.) November 13, 2003	
S	TATEMENT	BY A	APPI ICANT	First Named Inventor	Stephen TOMLINSON	
ľ	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,		Art Unit	1653	
	(Use as many si	he ets as	necess ary)	Examiner Name	Not Yet Assigned	
Sheet 7 of 8		Attorney Docket Number	577712000200			

127.	Senter, P.D. et al. (January/February 1993). "Generation of Cytotoxic Agents by Targeted Enzymes," Bioconjugate Chem. 4(1):3-9.	
128.	Seya, T. et al. (1985). "Limited Proteolysis of Complement Protein C3b by Regulatory Enzyme C3b Inactivator: Isolation and Characterization of a Biologically Active Fragment, C3d,g," J. Biochem. 97(1):373-382.	
129.	Sharkey, R.M. et al. (April 15, 1990). "Blodistribution and Radiation Dose Estimates for Yttrium- and lodine-Labeled Monoclonal Antibody IgG and Fragments in Nude Mice Bearing Human Colonic Tumor Xenografts," Cancer Res. 50:2330-2336.	
130.	Sharkey, R.M. et al. (June 15, 1991). "Rapid Blood Clearance of Immunoglobulin G2a and Immunoglobulin G2b in Nude Mice," Cancer Res. 51:3102-3107.	
131.	Sheerin, N.S. et al. (October 2002). "Leaked Protein and Interstitial Damage in the Kidney: Is Complement the Missing Link?" Clin. Exp. Immunol. 130(1):1-3.	
132.	Smith, G.P. et al. (2001). "Membrane-Targeted Complement Inhibitors," Mol. Immunol. 38:249-255.	
133.	Song, H. et al. (June 2003). "Complement Receptor 2-Mediated Targeting of Complement Inhibitors to Sites of Complement Activation," J. Clin. Invest. 111(12):1875-1885.	
134.	Sugita, Y. et al. (May 1994). "Recombinant Soluble CD59 Inhibits Reactive Haemolysis with Complement," <i>Immunology</i> 82(1):34-41.	
135.	Supplementary Partial European Search Report mailed April 3, 2006, for EP Application No. 03796403.8 filed November 13, 2003, three pages.	
136.	Supplementary European Search Report mailed July 3, 2006, for EP Application No. 03796403.8 filed November 13, 2003, four pages.	
137.	Szakonyi, G. et al. (June 1, 2001). "Structure of Complement Receptor 2 in Complex with Its C3d Ligand," Science 292(5522):1725-1728.	
138.	Takeda, J. et al. (1986). "Number of Hits Necessary for Complement-Mediated Hemolysis," Microbiol. Immunol. 30(5):461-468.	
139.	Ten, R.M. et al. (October 1, 1999). "The Signal Transduction Pathway of CD23 (FcεRlib) Targets IκB Kinase," <i>J. Immunol.</i> 163(7):3851-3857.	
140.	Tsutsumi, Y. et al. (July 18, 2000). "Site-Specific Chemical Modification with Polyethylene Glycol of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) Improves Antitumor Activity and Reduces Animal Toxicity and Immunogenicity," <i>Proc. Natl. Acad. Sci. USA</i> 97(15):8548- 8553.	
141.	Wang, Y. et al. (September 12, 1995). "Anti-C5 Monoclonal Antibody Therapy Prevents Collagen-Induced Arthritis and Ameliorates Established Disease," <i>Proc. Natl. Acad. Sci. USA</i> 92(19):8955-8959.	
142.	Wang, Y. et al. (August 6, 1996). "Amelioration of Lupus-Like Autoimmune Disease in NZB/W Fr, Mice After Treatment with a Blocking Monoclonal Antibody Specific for Complement Component C5," Proc. Natl. Acad. Sci. USA 93(16):8563-8568.	
143.	Ward, T. et al. (November 1, 1994). "Decay-Accelerating Factor CD55 is Identified as the Receptor for Echovirus 7 Using CELICS, a Rapid Immuno-Focal Cloning Method," EMBO J. 13(21):5070-5074.	
144.	Weisman, H.F. et al. (July 13, 1990). "Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis," Science 249(4965):146-151.	
145.	Whiss, P.A. (2002). "Pexelizumab Alexion," Curr. Opin. Investig. Drugs 3(6):870-877.	
 146.	Wiles, A.P. et al. (1997). "NMR Studies of a Viral Protein that Mimics the Regulators of Complement Activation," J. Mol. Biol. 272(2):253-265.	
147.	Yu, J. et al. (January 1999). "Protection of Human Breast Cancer Cells from Complement-Mediated Lysis by Expression of Heterologous CD59." Clin. Exp. Immunol. 115(1):13-18.	

Examiner	Date
Signature	Considered
pa- 1146261	

	Substitute for form 1449/PTO			Complete if Known		
Suc				Application Number	10/534,772	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	(Int'l.) November 13, 2003	
				First Named Inventor	Stephen TOMLINSON	
				Art Unit	1653	
				Examiner Name	Not Yet Assigned	
Sheet	8	of	8	Attorney Docket Number	577712000200	

	Zhang, H-F. et al. (January 1999). "Targeting of Functional Antibody-CD59 Fusion Proteins to a Cell Surface," <i>J. Clin. Invest.</i> 103(1):55-66.	
149.	Zhang, H-F. et al. (July 20, 2001). "Targeting of Functional Antibody-Decay-Accelerating Factor Fusion Proteins to a Cell Surface," J. Biol. Chem. 276(29):27290-27295.	
	Zipfel, P.F. (June 2001). "Complement Factor H: Physiology and Pathophysiology," Seminars in Thrombosis Hemostasis 27(3):191-199.	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark hare if English language Translation is attached,